David Hyman, Ph.D. - Publications

Affiliations: 
2010 English City University of New York, New York, NY, United States 
Area:
Rhetoric and Composition Language, American Literature, Multimedia Communications

426 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Choudhry NK, Kronish IM, Vongpatanasin W, Ferdinand KC, Pavlik VN, Egan BM, Schoenthaler A, Houston Miller N, Hyman DJ. Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association. Hypertension (Dallas, Tex. : 1979). HYP0000000000000203. PMID 34615363 DOI: 10.1161/HYP.0000000000000203  1
2021 Feldman RC, Hyman DA, Price WN, Ratain MJ. Negative innovation: when patents are bad for patients. Nature Biotechnology. 39: 914-916. PMID 34376839 DOI: 10.1038/s41587-021-00999-0  1
2021 Smyth LM, Reichel JB, Tang J, Patel JAA, Meng F, Selcuklu DS, Houck-Loomis B, You D, Samoila A, Schiavon G, Li BT, Razavi P, Piscuoglio S, Reis-Filho JS, Taylor BS, ... ... Hyman DM, et al. Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study. Jco Precision Oncology. 5. PMID 34250397 DOI: 10.1200/PO.20.00184  1
2021 Tabernero J, Hyman DM, Soria JC. José "Pepe" Baselga, MD, PhD: In Memoriam (1959-2021). Cancer Discovery. PMID 33883166 DOI: 10.1158/2159-8290.CD-21-0458  1
2021 Kummar S, Berlin J, Mascarenhas L, van Tilburg CM, Geoerger B, Lassen UN, Schilder RJ, Turpin B, Nanda S, Keating K, Childs BH, Chirila C, Laetsch TW, Hyman DM, Drilon A, et al. Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib. Current Problems in Cancer. 100734. PMID 33865615 DOI: 10.1016/j.currproblcancer.2021.100734  1
2021 Smyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Jhaveri K, Varga A, Wong A, Schram AM, Ambrose H, Carr TH, de Bruin EC, Salinas-Souza C, Foxley A, ... ... Hyman DM, et al. Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. Npj Breast Cancer. 7: 44. PMID 33863913 DOI: 10.1038/s41523-021-00251-7  1
2021 Hyman DM, Soria JC, Tabernero J. Building Bridges Between Drug Development and Cancer Science: A Tribute to José Baselga's Legacy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 33838220 DOI: 10.1016/j.annonc.2021.03.209  1
2021 Adib E, Klonowska K, Giannikou K, Do KT, Pruitt-Thompson S, Bhushan K, Milstein MI, Hedglin J, Kargus K, Sholl LM, Tsuji J, Hyman DM, Sisk AE, Shapiro GI, Vargas HA, et al. Phase II clinical trial of everolimus in a pan-cancer cohort of patients with mTOR pathway alterations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33727259 DOI: 10.1158/1078-0432.CCR-20-4548  1
2021 Kundra R, Zhang H, Sheridan R, Sirintrapun SJ, Wang A, Ochoa A, Wilson M, Gross B, Sun Y, Madupuri R, Satravada BA, Reales D, Vakiani E, Al-Ahmadie HA, Dogan A, ... ... Hyman D, et al. OncoTree: A Cancer Classification System for Precision Oncology. Jco Clinical Cancer Informatics. 5: 221-230. PMID 33625877 DOI: 10.1200/CCI.20.00108  1
2021 Wu J, Liu D, Offin M, Lezcano C, Torrisi JM, Brownstein S, Hyman DM, Gounder MM, Abida W, Drilon A, Harding JJ, Sullivan RJ, Janku F, Welsch D, Varterasian M, et al. Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers. Investigational New Drugs. PMID 33389388 DOI: 10.1007/s10637-020-01035-9  1
2020 Italiano A, Nanda S, Briggs A, Garcia-Foncillas J, Lassen U, Vassal G, Kummar S, van Tilburg CM, Hong DS, Laetsch TW, Keating K, Reeves JA, Fellous M, Childs BH, Drilon A, ... Hyman DM, et al. Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis. Cancers. 12. PMID 33158040 DOI: 10.3390/cancers12113246  1
2020 Jhaveri K, Chang MT, Juric D, Saura C, Gambardella V, Melnyk A, Patel MR, Ribrag V, Ma CX, Aljumaily R, Bedard PL, Sachdev JC, Dunn L, Won HH, Bond J, ... ... Hyman DM, et al. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with -Mutant Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33148674 DOI: 10.1158/1078-0432.CCR-20-2657  1
2020 Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, Patel M, Berthon A, Syed A, Yabe M, Coombs CC, Caltabellotta NM, Walsh M, Offit K, Stadler Z, ... ... Hyman DM, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics. PMID 33106634 DOI: 10.1038/s41588-020-00710-0  1
2020 Selenica P, Conlon N, Gonzalez C, Frosina D, Jungbluth AA, Beets-Tan RGH, Rao MK, Zhang Y, Benayed R, Ladanyi M, Solit DB, Chiang S, Hyman DM, Hensley ML, Soslow RA, et al. Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic Differentiation. The American Journal of Surgical Pathology. PMID 32889887 DOI: 10.1097/PAS.0000000000001572  1
2020 Mondaca SP, Liu D, Flynn JR, Badson S, Hamaway S, Gounder MM, Khalil DN, Drilon AE, Li BT, Jhaveri KL, Schram AM, Kargus KE, Kasler MK, Blauvelt NM, Segal NH, ... ... Hyman DM, et al. Clinical implications of drug-induced liver injury in early-phase oncology clinical trials. Cancer. PMID 32809222 DOI: 10.1002/Cncr.33153  1
2020 Goldstein DA, Strohbehn GW, Serritella AV, Hyman DA, Lichter AS, Ratain MJ. Interventional Pharmacoeconomics. Cancer Journal (Sudbury, Mass.). 26: 330-334. PMID 32732676 DOI: 10.1097/PPO.0000000000000461  0.01
2020 Hyman DA, Silver C. Pricing and Paying for Cancer Drugs: Policy Options for Fixing A Broken System. Cancer Journal (Sudbury, Mass.). 26: 298-303. PMID 32732672 DOI: 10.1097/PPO.0000000000000457  1
2020 Oaknin A, Friedman CF, Roman LD, D'Souza A, Brana I, Clement-Bidard F, Goldman J, Alvarez EA, Boni V, ElNaggar AC, Passalacqua R, Do KTM, Santin AD, Keyvanjah K, Xu F, ... ... Hyman DM, et al. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial. Gynecologic Oncology. PMID 32723675 DOI: 10.1016/j.ygyno.2020.07.025  1
2020 Vaughan EM, Hyman DJ, Naik AD, Samson SL, Razjouyan J, Foreyt JP. A Telehealth-supported, Integrated care with CHWs, and MEdication-access (TIME) Program for Diabetes Improves HbA1c: a Randomized Clinical Trial. Journal of General Internal Medicine. PMID 32700217 DOI: 10.1007/s11606-020-06017-4  1
2020 Ulaner GA, Carrasquillo JA, Riedl CC, Yeh R, Hatzoglou V, Ross DS, Jhaveri K, Chandarlapaty S, Hyman DM, Zeglis BM, Lyashchenko SK, Lewis JS. Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted Zr-Pertuzumab PET/CT. Radiology. 192828. PMID 32515679 DOI: 10.1148/Radiol.2020192828  1
2020 Francis JH, Diamond EL, Chi P, Jaben K, Hyman DM, Abramson DH. MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR Variants. Ocular Oncology and Pathology. 6: 159-163. PMID 32509759 DOI: 10.1159/000501155  1
2020 Ross DS, Liu B, Schram AM, Razavi P, Lagana SM, Zhang Y, Scaltriti M, Bromberg JF, Ladanyi M, Hyman DM, Drilon A, Zehir A, Benayed R, Chandarlapaty S, Hechtman JF. Enrichment of Kinase Fusions in ESR1 Wild Type, Metastatic Breast Cancer Revealed by a Systematic Analysis of 4,854 Patients. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32348852 DOI: 10.1016/J.Annonc.2020.04.008  1
2020 Smyth LM, Tamura K, Oliveira M, Ciruelos EM, Mayer IA, Sablin MP, Biganzoli L, Ambrose HJ, Ashton J, Barnicle A, Cashell DD, Corcoran C, de Bruin EC, Foxley A, Hauser J, ... ... Hyman DM, et al. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With -Mutant, ER-Positive Metastatic Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32312891 DOI: 10.1158/1078-0432.CCR-19-3953  1
2020 Hensley ML, Chavan SS, Solit DB, Murali R, Soslow R, Chiang S, Jungbluth AA, Bandlamudi C, Srinivasan P, Tap WD, Rosenbaum E, Taylor BS, Donoghue MTA, Hyman DM. Genomic Landscape of Uterine Sarcomas Defined through Prospective Clinical Sequencing. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32299819 DOI: 10.1158/1078-0432.CCR-19-3959  1
2020 Murciano-Goroff YR, Taylor BS, Hyman DM, Schram AM. Toward a More Precise Future for Oncology. Cancer Cell. 37: 431-442. PMID 32289268 DOI: 10.1016/j.ccell.2020.03.014  1
2020 Bedard PL, Hyman DM, Davids MS, Siu LL. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet (London, England). 395: 1078-1088. PMID 32222192 DOI: 10.1016/S0140-6736(20)30164-1  0.01
2020 Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, Shifman S, Tu HY, Myers ML, Xu C, Mattar M, Khodos I, Little M, Qeriqi B, Weitsman G, ... ... Hyman DM, et al. HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discovery. PMID 32213539 DOI: 10.1158/2159-8290.Cd-20-0215  1
2020 Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van Tilburg CM, Nagasubramanian R, Berlin JD, Federman N, Mascarenhas L, Geoerger B, Dowlati A, Pappo AS, Bielack S, ... ... Hyman DM, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. The Lancet. Oncology. PMID 32105622 DOI: 10.1016/S1470-2045(19)30856-3  1
2020 Subbiah V, Puzanov I, Blay JY, Chau I, Lockhart AC, Raje NS, Wolf J, Baselga J, Meric-Bernstam F, Roszik J, Diamond EL, Riely GJ, Sherman EJ, Riehl T, Pitcher B, ... Hyman DM, et al. Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. Cancer Discovery. PMID 32029534 DOI: 10.1158/2159-8290.CD-19-1265  1
2020 Vaughan EM, Rueda JJ, Samson SL, Hyman DJ. Reducing the burden of diabetes treatment: A review of low-cost oral hypoglycemic medications. Current Diabetes Reviews. PMID 32026779 DOI: 10.2174/1573399816666200206112318  1
2020 Bhatia A, Hatzoglou V, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Yabe M, Petrova-Drus K, Panageas KS, Reiner A, Rosenblum M, Diamond EL. Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. Neuro-Oncology. PMID 31950179 DOI: 10.1093/neuonc/noaa008  1
2020 Smyth LM, Zhou Q, Nguyen B, Yu C, Lepisto EM, Arnedos M, Hassett MJ, Lenoue-Newton ML, Blauvelt N, Dogan S, Micheel CM, Wathoo C, Horlings H, Hudecek J, Gross BE, ... ... Hyman DM, et al. Characteristics and outcome of AKT1 E17K-mutant breast cancer defined through AACR GENIE, a clinicogenomic registry. Cancer Discovery. PMID 31924700 DOI: 10.1158/2159-8290.Cd-19-1209  1
2020 van Beek EJAH, Hernandez JM, Goldman DA, Davis JL, McLoughlin KC, Ripley RT, Kim TS, Tang LH, Hechtman JF, Zheng J, Capanu M, Schultz N, Hyman DM, Ladanyi M, Berger MF, et al. Correction to: Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. Annals of Surgical Oncology. PMID 31898094 DOI: 10.1245/S10434-019-08107-Y  1
2020 Murciano-Goroff YR, Lebow ES, Tu H, Li M, Lim LP, Arbour KC, Travis W, Solit DB, Ladanyi M, Jones DR, Rudin CM, Martinez A, Myers ML, Makhnin A, Razavi P, ... ... Hyman DM, et al. Abstract 12: Characterizing KRAS G12C and other mutations in plasma ctDNA from patients with lung cancer Clinical Cancer Research. 26: 12-12. DOI: 10.1158/1557-3265.Advprecmed20-12  1
2020 Reynolds T, Jack K, Kemeny M, Bulone L, Gonsky J, Kampel LJ, Hyman D, Solit DB, Conklin C, McMillan S, DeSimone N, Galle J, Naupari S, Brown CL. Abstract A090: Community partnerships expand access to tumor molecular profiling Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp19-A090  1
2020 Wildiers H, Boni V, Saura C, Oliveira M, Jhaveri K, Won H, Bidard F, Brufsky AM, Burkard ME, Cervantes A, Fernández-Martos C, Haley B, Loi S, Spanggaard I, Panni S, ... ... Hyman DM, et al. Abstract P1-19-08: Neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT ‘basket’ trial Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P1-19-08  1
2020 Smyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Schram A, Varga A, Wong A, Ambrose H, Barnicle A, Carr TH, Bruin ECd, Salinas-Souza C, Foxley A, ... ... Hyman DM, et al. Abstract P1-19-05: Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER+ metastatic breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P1-19-05  1
2020 Murciano-Goroff YR, Arbour KC, Offin MD, Tu HY, Lebow ES, Shaffer TS, Bertucci C, Hosseini SA, Garg K, Lim LP, Li M, Chang JC, Reis-Filho JS, Razavi P, Isbell JM, ... ... Hyman DM, et al. Abstract 709: The utility of plasma ctDNA for detection ofKRASG12C and other mutations in lung cancers Clinical Trials. DOI: 10.1158/1538-7445.Am2020-709  1
2020 Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Patel M, Berthon A, Syed A, Yabe M, Coombs C, Caltabellotta NM, Walsh M, Offit K, Stadler Z, Lee C, ... ... Hyman D, et al. Abstract 5703: Oncologic therapy shapes the fitness landscape of clonal hematopoiesis Tumor Biology. DOI: 10.1158/1538-7445.Am2020-5703  1
2020 Cocco E, Lee JE, Kannan S, Schram AM, Won HH, Shifman S, Kulick A, Baldino L, Toska E, Arena S, Mussolin B, Kannan R, Vasan N, Gorelick AN, Berger MF, ... ... Hyman DM, et al. Abstract 5680: TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors Cancer Research. 80: 5680-5680. DOI: 10.1158/1538-7445.Am2020-5680  1
2019 Subbiah V, Gervais R, Riely G, Hollebecque A, Blay JY, Felip E, Schuler M, Gonçalves A, Italiano A, Keedy V, Chau I, Puzanov I, Raje NS, Meric-Bernstam F, Makrutzki M, ... ... Hyman DM, et al. Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. Jco Precision Oncology. 3. PMID 32914022 DOI: 10.1200/PO.18.00266  1
2019 Tao JJ, Eubank MH, Schram AM, Cangemi N, Pamer E, Rosen EY, Schultz N, Chakravarty D, Philip J, Hechtman JF, Harding JJ, Smyth LM, Jhaveri KL, Drilon A, Ladanyi M, ... ... Hyman DM, et al. Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology. Jco Precision Oncology. 3. PMID 32914018 DOI: 10.1200/PO.19.00066  1
2019 Carlo MI, Khan N, Zehir A, Patil S, Ged Y, Redzematovic A, Coskey DT, Hyman DM, Ladanyi M, Chen YB, Robson M, Hakimi AA, Lee CH, Feldman DR, Gao J, et al. Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets. Jco Precision Oncology. 3. PMID 32914011 DOI: 10.1200/PO.18.00372  1
2019 Rosen EY, Schram AM, Young RJ, Schreyer MW, Hechtman JF, Shu CA, Ku NC, Hyman DM, Drilon A. Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors. Jco Precision Oncology. 3. PMID 32914009 DOI: 10.1200/PO.19.00009  1
2019 Cadoo KA, Mandelker DL, Mukherjee S, Stewart C, DeLair D, Ravichandran V, Srinivasan P, Hurley D, Kemel Y, Arnold AG, Sheehan M, Pradhan N, Joseph V, Chi DS, Gardner GJ, ... ... Hyman D, et al. Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer. Jco Precision Oncology. 3. PMID 32775946 DOI: 10.1200/po.18.00338  1
2019 Hyman DM, Ladanyi M. Foreword. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: viii1-viii2. PMID 32223933 DOI: 10.1093/annonc/mdz409  1
2019 Matos I, Goyal L, Cleary J, Voss M, Oh D, Bernstam FM, Ng C, Iyer G, Ishii N, Hu Y, Chessex AV, Pokorska-Bocci A, Nicolas V, Kirpicheva Y, Zanna C, ... ... Hyman D, et al. Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: iv122-iv123. PMID 32085006 DOI: 10.1093/annonc/mdz157.002  1
2019 Rubinstein MM, Hyman DM, Caird I, Won H, Soldan K, Seier K, Iasonos A, Tew WP, O'Cearbhaill RE, Grisham RN, Hensley ML, Troso-Sandoval T, Sabbatini P, Guillen J, Selcuklu SD, et al. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Cancer. PMID 31880826 DOI: 10.1002/cncr.32677  1
2019 Rosen EY, Goldman DA, Hechtman JF, Benayed R, Schram AM, Cocco E, Shifman S, Gong Y, Kundra R, Solomon JP, Bardelli A, Scaltriti M, Drilon A, Iasonos A, Taylor BS, ... Hyman DM, et al. TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31871300 DOI: 10.1158/1078-0432.CCR-19-3165  1
2019 Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, ... ... Hyman DM, et al. Author Correction: Tumour lineage shapes BRCA-mediated phenotypes. Nature. PMID 31822847 DOI: 10.1038/s41586-019-1839-2  1
2019 Smyth LM, Piha-Paul SA, Won HH, Schram AM, Saura C, Loi S, Lu J, Shapiro GI, Juric D, Mayer IA, Arteaga CL, de la Fuente MI, Brufksy AM, Spanggaard I, Mau-Sorensen M, ... ... Hyman DM, et al. Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer Discovery. PMID 31806627 DOI: 10.1158/2159-8290.Cd-19-0966  1
2019 Razavi P, Li BT, Brown DN, Jung B, Hubbell E, Shen R, Abida W, Juluru K, De Bruijn I, Hou C, Venn O, Lim R, Anand A, Maddala T, Gnerre S, ... ... Hyman DM, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nature Medicine. PMID 31768066 DOI: 10.1038/S41591-019-0652-7  1
2019 Durham BH, Lopez Rodrigo E, Picarsic J, Abramson D, Rotemberg V, De Munck S, Pannecoucke E, Lu SX, Pastore A, Yoshimi A, Mandelker D, Ceyhan-Birsoy O, Ulaner GA, Walsh M, Yabe M, ... ... Hyman DM, et al. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nature Medicine. PMID 31768065 DOI: 10.1038/S41591-019-0653-6  1
2019 Stasenko M, Tunnage I, Ashley CW, Rubinstein MM, Latham AJ, Da Cruz Paula A, Mueller JJ, Leitao MM, Friedman CF, Makker V, Soslow RA, DeLair DF, Hyman DM, Zamarin D, Alektiar KM, et al. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Gynecologic Oncology. PMID 31757464 DOI: 10.1016/j.ygyno.2019.10.028  1
2019 Penson A, Camacho N, Zheng Y, Varghese AM, Al-Ahmadie H, Razavi P, Chandarlapaty S, Vallejo CE, Vakiani E, Gilewski T, Rosenberg JE, Shady M, Tsui DWY, Reales DN, Abeshouse A, ... ... Hyman DM, et al. Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. Jama Oncology. PMID 31725847 DOI: 10.1001/Jamaoncol.2019.3985  1
2019 Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 575: 299-309. PMID 31723286 DOI: 10.1038/s41586-019-1730-1  1
2019 Ulaner GA, Saura C, Piha-Paul SA, Mayer IA, Quinn DI, Jhaveri K, Stone B, Shahin S, Mann G, Dujka M, Bryce R, Meric-Bernstam F, Solit DB, Hyman DM. Impact of FDG PET Imaging for Expanding Patient Eligibility & Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31548342 DOI: 10.1158/1078-0432.Ccr-19-1658  1
2019 Hyman DA, Silver C. Why are we Being Overcharged for Pharmaceuticals? What Should We Do About It? The Journal of Legal Medicine. 39: 137-149. PMID 31503533 DOI: 10.1080/01947648.2019.1645542  1
2019 Guo R, Schreyer M, Chang JC, Rothenberg SM, Henry D, Cotzia P, Kris MG, Rekhtman N, Young RJ, Hyman DM, Drilon A. Response to Selective RET Inhibition With LOXO-292 in a Patient With Fusion-Positive Lung Cancer With Leptomeningeal Metastases. Jco Precision Oncology. 3. PMID 31485557 DOI: 10.1200/PO.19.00021  1
2019 Cocco E, Schram AM, Kulick A, Misale S, Won HH, Yaeger R, Razavi P, Ptashkin R, Hechtman JF, Toska E, Cownie J, Somwar R, Shifman S, Mattar M, Selçuklu SD, ... ... Hyman DM, et al. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nature Medicine. PMID 31406350 DOI: 10.1038/S41591-019-0542-Z  1
2019 Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, Jungbluth AA, Zehir A, Benayed R, Drilon A, Hyman DM, Ladanyi M, Sireci AN, Hechtman JF. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 31375766 DOI: 10.1038/s41379-019-0324-7  1
2019 Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, ... ... Hyman DM, et al. Tumour lineage shapes BRCA-mediated phenotypes. Nature. PMID 31292550 DOI: 10.1038/s41586-019-1382-1  1
2019 Jonsson P, Lin AL, Young RJ, DiStefano NM, Hyman DM, Li BT, Berger MF, Zehir A, Ladanyi M, Solit DB, Arnold AG, Stadler ZK, Mandelker D, Goldberg ME, Chmielecki J, et al. Genomic correlates of disease progression and treatment response in prospectively characterized gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31263031 DOI: 10.1158/1078-0432.Ccr-19-0032  1
2019 George GC, Barata PC, Campbell A, Chen A, Cortes JE, Hyman DM, Jones L, Karagiannis T, Klaar S, Le-Rademacher JG, LoRusso P, Mandrekar SJ, Merino DM, Minasian LM, Mitchell SA, et al. Improving attribution of adverse events in oncology clinical trials. Cancer Treatment Reviews. 76: 33-40. PMID 31108240 DOI: 10.1016/J.Ctrv.2019.04.004  0.01
2019 Tao JJ, Cangemi NA, Makker V, Cadoo K, Liu JF, Rasco DW, Navarro WH, Haqq CM, Hyman DM. First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31068369 DOI: 10.1158/1078-0432.CCR-19-1065  1
2019 Benayed R, Offin M, Mullaney K, Sukhadia P, Rios K, Desmeules P, Ptashkin RN, Won H, Chang J, Halpenny DF, Schram AM, Rudin CM, Hyman DM, Arcila ME, Berger MF, et al. High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31028088 DOI: 10.1158/1078-0432.CCR-19-0225  1
2019 Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, Di Simone C, Hyman DM, Stepan DE, Dutcus CE, Schmidt EV, Guo M, Sachdev P, Shumaker R, Aghajanian C, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. The Lancet. Oncology. PMID 30922731 DOI: 10.1016/S1470-2045(19)30020-8  1
2019 Diamond EL, Reiner AS, Buthorn JJ, Shuk E, Applebaum AJ, Hyman DM, Abdel-Wahab O, Rampal R, Janku F, Brewer K, Campbell J, Mao JJ, Atkinson TM, Panageas KS. A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease. Blood Advances. 3: 934-938. PMID 30917949 DOI: 10.1182/Bloodadvances.2018030502  1
2019 Slotkin EK, Diolaiti D, Shukla NN, Dela Cruz FS, Clark JJ, Gundem G, Yellapantula VD, Levine MF, You D, Ma P, Pachhal S, Ibanez Sanchez G, Benayed R, Jungbluth AA, Smyth LM, ... ... Hyman DM, et al. Patient-driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-driven Cancer. Cancer Discovery. PMID 30877085 DOI: 10.1158/2159-8290.Cd-18-0953  1
2019 Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, ... ... Hyman DM, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. PMID 30867592 DOI: 10.1038/S41586-019-1012-Y  1
2019 Vaughan EM, Naik AD, Lewis CM, Foreyt JP, Samson SL, Hyman DJ. Telemedicine Training and Support for Community Health Workers: Improving Knowledge of Diabetes. Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association. PMID 30839244 DOI: 10.1089/tmj.2018.0313  1
2019 Feit NZ, Goldman DA, Smith E, Deighan J, Iasonos A, Zivanovic O, Hyman DM. Use, Safety, and Efficacy of Single-Patient Use of the US Food and Drug Administration Expanded Access Program. Jama Oncology. PMID 30816938 DOI: 10.1001/jamaoncol.2018.7002  1
2019 Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, et al. Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. PMID 30755741 DOI: 10.1038/S41586-019-0974-0  1
2019 Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, et al. Correction: An Acquired Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. Cancer Discovery. 9: 303. PMID 30737217 DOI: 10.1158/2159-8290.Cd-18-1515  1
2019 Condorelli R, Mosele F, Verret B, Bachelot T, Bedard PL, Cortes J, Hyman DM, Juric D, Krop I, Bieche I, Saura C, Sotiriou C, Cardoso F, Loibl S, Andre F, et al. Genomic alterations in breast cancer: Level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30715161 DOI: 10.1093/annonc/mdz036  1
2019 Cocco E, Benhamida J, Middha S, Zehir A, Mullaney K, Shia J, Yaeger R, Zhang L, Wong D, Villafania L, Nafa K, Scaltriti M, Drilon A, Saltz L, Schram AM, ... ... Hyman DM, et al. Colorectal carcinomas containing hypermethylated MLH1 promoter and wild type BRAF/KRAS are enriched for targetable kinase fusions. Cancer Research. PMID 30643016 DOI: 10.1158/0008-5472.Can-18-3126  1
2019 Varghese AM, Patel JAA, Janjigian YY, Meng F, Selcuklu SD, Zimel C, Hyman DM, Iyer G, Houck-Loomis B, Abou-Alfa GK, Berger MF, Lowery MA. Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations. Journal of Clinical Oncology. 37: 4096-4096. DOI: 10.1200/Jco.2019.37.15_Suppl.4096  1
2019 Dunbar A, Bolton K, Devlin SM, Sanchez-Vega F, Gao J, Mones JV, Wills JM, Kelly D, Farina M, Kishore S, Juluru K, Iyengar N, Hyman DM, Zehir A, Park W, et al. Extended Mutational Profiling By MSK-IMPACTTM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy Blood. 134: 633-633. DOI: 10.1182/Blood-2019-124242  1
2019 Won HH, Selcuklu SD, Piha-Paul SA, Saura C, Rodon J, Mayer IA, Loi S, Shapiro GI, Lu J, Brufsky A, Zimel C, Melcer M, Scaltriti M, Eli LD, Cutler RE, ... ... Hyman DM, et al. Abstract 929: Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT "Basket" Trial Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-929  1
2019 Srinivasan P, Bandlamudi C, Shia J, Latham AS, Jonsson P, Penson A, Middha S, Hechtman J, Zehir A, Richards A, Chawan S, Kemel Y, Mandelker D, Zhang L, Hyman D, et al. Abstract 4158: Dissecting the role of zygosity and lineage in Lynch Syndrome-associated microsatellite Instability Epidemiology. DOI: 10.1158/1538-7445.Sabcs18-4158  1
2019 Patel J, Hasan M, Meng F, Jing X, Tam G, Johnson I, Zheng Y, Bandlamudi C, Stewart C, Won H, Hampton O, Schram A, Rosen E, Drilon A, Varghese A, ... Hyman D, et al. Abstract 2516: A bioinformatics framework for high-sensitivity detection and monitoring of oncogenic gene fusions in plasma cfDNA Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2516  1
2019 Bolton K, Ptashkin R, Braunstein L, Gao T, Devlin SM, Kelly D, Coombs C, Patel M, Moarii M, Bernard E, Berthon A, Boucai L, Glodzik D, Martin A, Stadler Z, ... ... Hyman D, et al. Abstract LB-304: Oncologic therapy for solid tumors alters the risk of clonal hematopoiesis Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-304  1
2019 Cocco E, Kulick A, Misale S, Yaeger R, Razavi P, Won HH, Ptashkin R, Hechtman JF, Toska E, Cownie J, Somwar R, Shifman S, Mattar M, Selçuklu SD, Samoila A, ... ... Hyman DM, et al. Abstract LB-118: Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-118  1
2019 Hyman D, Kummar S, Farago A, Geoerger B, Mau-Sorensen M, Taylor M, Garralda E, Nagasubramanian R, Natheson M, Song L, Capra M, Jorgensen M, Ho A, Shukla N, Smith S, et al. Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi) Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct127  1
2019 Schram A, Spreafico A, Oliva M, Brana I, Garralda E, Lakhani N, Hoff DV, Borazanci E, Pandya N, Hoffman K, Hallett R, Giblin P, Anido J, Kelly A, Wasserman R, ... ... Hyman DM, et al. Abstract CT014: Initial results from the Phase I study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct014  1
2018 Raje N, Chau I, Hyman DM, Ribrag V, Blay JY, Tabernero J, Elez E, Wolf J, Yee AJ, Kaiser M, Landau H, Michot JM, Hollebecque A, Veronese L, Makrutzki M, et al. Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring Mutations: A Cohort of the Histology-Independent VE-BASKET Study. Jco Precision Oncology. 2. PMID 32913989 DOI: 10.1200/PO.18.00070  1
2018 Schram AM, Jonsson P, Drilon A, Bale TA, Hechtman JF, Benayed R, Hanusch B, Young RJ, Grommes C, Ku N, Kaley T, Hyman DM, Taylor BS. Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent Glioma. Jco Precision Oncology. 2. PMID 31218270 DOI: 10.1200/PO.18.00089  1
2018 Gupta S, Vanderbilt CM, Cotzia P, Arias Stella JA, Chang JC, Zehir A, Benayed R, Nafa K, Razavi P, Hyman DM, Baselga J, Berger MF, Ladanyi M, Arcila ME, Ross DS. Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management. The Journal of Molecular Diagnostics : Jmd. PMID 30576871 DOI: 10.1016/J.Jmoldx.2018.10.006  1
2018 Yao Z, Gao Y, Su W, Yaeger R, Tao J, Na N, Zhang Y, Zhang C, Rymar A, Tao A, Timaul NM, Mcgriskin R, Outmezguine NA, Zhao H, Chang Q, ... ... Hyman DM, et al. RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nature Medicine. PMID 30559419 DOI: 10.1038/S41591-018-0274-5  1
2018 Boland JL, Zhou Q, Martin M, Callahan MK, Konner J, O'Cearbhaill RE, Friedman CF, Tew W, Makker V, Grisham RN, Hensley ML, Zecca N, Iasonos AE, Snyder A, Hyman DM, et al. Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. Gynecologic Oncology. PMID 30470581 DOI: 10.1016/J.Ygyno.2018.11.025  1
2018 Schram AM, Gandhi L, Mita MM, Damstrup L, Campana F, Hidalgo M, Grande E, Hyman DM, Heist RS. A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours. British Journal of Cancer. PMID 30425349 DOI: 10.1038/s41416-018-0322-4  1
2018 Vaughan EM, Johnston CA, Arlinghaus KR, Hyman DJ, Foreyt JP. A Narrative Review of Diabetes Group Visits in Low-Income and Underserved Settings. Current Diabetes Reviews. PMID 30421682 DOI: 10.2174/1573399814666181112145910  1
2018 Bielski CM, Donoghue MTA, Gadiya M, Hanrahan AJ, Won HH, Chang MT, Jonsson P, Penson AV, Gorelick A, Harris C, Schram AM, Syed A, Zehir A, Chapman PB, Hyman DM, et al. Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. Cancer Cell. PMID 30393068 DOI: 10.1016/J.Ccell.2018.10.003  1
2018 Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Mandelker D, Middha S, Hechtman J, Zehir A, Dubard-Gault M, Tran C, Stewart C, Sheehan M, Penson A, DeLair D, ... ... Hyman DM, et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1800283. PMID 30376427 DOI: 10.1200/Jco.18.00283  1
2018 Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, Shia J, Hechtman JF, Kundra R, El Dika I, Do RK, Sun Y, Kingham TP, D'Angelica MI, Berger MF, ... Hyman DM, et al. Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30373752 DOI: 10.1158/1078-0432.CCR-18-2293  1
2018 Harding JJ, Lowery MA, Shih AH, Schvartzman JM, Hou S, Famulare C, Patel M, Roshal M, Do RK, Zehir A, You D, Selcuklu SD, Viale A, Tallman MS, Hyman DM, et al. Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition. Cancer Discovery. PMID 30355724 DOI: 10.1158/2159-8290.Cd-18-0877  1
2018 Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, Keedy V, Bielle F, Hofheinz RD, Joly F, Blay JY, Chau I, Puzanov I, Raje NS, Wolf J, ... ... Hyman DM, et al. BRAF Inhibition in BRAF-Mutant Gliomas: Results From the VE-BASKET Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018789990. PMID 30351999 DOI: 10.1200/JCO.2018.78.9990  1
2018 Hyman DA. The Medicalization of Poverty: A Dose of Theory. The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics. 46: 582-587. PMID 30336086 DOI: 10.1177/1073110518804200  0.01
2018 Cocco E, Javier Carmona F, Razavi P, Won HH, Cai Y, Rossi V, Chan C, Cownie J, Soong J, Toska E, Shifman SG, Sarotto I, Savas P, Wick MJ, Papadopoulos KP, ... ... Hyman DM, et al. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science Signaling. 11. PMID 30301790 DOI: 10.1126/Scisignal.Aat9773  1
2018 Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, ... ... Hyman DM, et al. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. 34: 427-438.e6. PMID 30205045 DOI: 10.1016/J.Ccell.2018.08.008  1
2018 Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, Schuster SJ, Rodriguez A, Hyman D, Calvo-Vidal MN, Smith SM, Svoboda J, Furman RR, Coleman M, Leonard JP. Five-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma. Blood. PMID 30181173 DOI: 10.1182/blood-2018-07-859769  0.01
2018 Drilon A, Ou SI, Cho BC, Kim DW, Lee J, Lin JJ, Zhu VW, Ahn MJ, Camidge DR, Nguyen J, Zhai D, Deng W, Huang Z, Rogers E, Liu J, ... ... Hyman DM, et al. Repotrectinib (TPX-0005) is a next generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent front mutations. Cancer Discovery. PMID 30093503 DOI: 10.1158/2159-8290.CD-18-0484  1
2018 Soumerai TE, Donoghue MTA, Bandlamudi C, Srinivasan P, Chang MT, Zamarin D, Cadoo K, Grisham R, O'Cearbhaill RE, Tew W, Konner J, Hensley ML, Makker V, Sabbatini PJ, Spriggs DR, ... ... Hyman DM, et al. CLINICAL UTILITY OF PROSPECTIVE MOLECULAR CHARACTERIZATION IN ADVANCED ENDOMETRIAL CANCER. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30068706 DOI: 10.1158/1078-0432.Ccr-18-0412  1
2018 Cheng ML, Berger MF, Hyman DM, Solit DB. Clinical tumour sequencing for precision oncology: time for a universal strategy. Nature Reviews. Cancer. PMID 30030494 DOI: 10.1038/s41568-018-0043-2  1
2018 Biswas C, Rao S, Slade K, Hyman D, Dersh D, Mantegazza AR, Zoltick PW, Marks MS, Argon Y, Behrens EM. Tyrosine 870 of TLR9 is critical for receptor maturation rather than phosphorylation-dependent ligand-induced signaling. Plos One. 13: e0200913. PMID 30024926 DOI: 10.1371/Journal.Pone.0200913  0.01
2018 Bielski CM, Zehir A, Penson AV, Donoghue MTA, Chatila W, Armenia J, Chang MT, Schram AM, Jonsson P, Bandlamudi C, Razavi P, Iyer G, Robson ME, Stadler ZK, Schultz N, ... ... Hyman DM, et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nature Genetics. PMID 30013179 DOI: 10.1038/S41588-018-0165-1  1
2018 Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, ... ... Hyman DM, et al. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018779777. PMID 29989854 DOI: 10.1200/Jco.2018.77.9777  1
2018 Carlo MI, Mukherjee S, Mandelker D, Vijai J, Kemel Y, Zhang L, Knezevic A, Patil S, Ceyhan-Birsoy O, Huang KC, Redzematovic A, Coskey DT, Stewart C, Pradhan N, Arnold AG, ... ... Hyman DM, et al. Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. Jama Oncology. PMID 29978187 DOI: 10.1001/Jamaoncol.2018.1986  1
2018 Taylor J, Pavlick D, Yoshimi A, Marcelus C, Chung SS, Hechtman JF, Benayed R, Cocco E, Durham BH, Bitner L, Inoue D, Chung YR, Mullaney K, Watts JM, Diamond EL, ... ... Hyman DM, et al. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. The Journal of Clinical Investigation. PMID 29920189 DOI: 10.1172/Jci120787  1
2018 Ptashkin RN, Mandelker DL, Coombs CC, Bolton K, Yelskaya Z, Hyman DM, Solit DB, Baselga J, Arcila ME, Ladanyi M, Zhang L, Levine RL, Berger MF, Zehir A. Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors. Jama Oncology. PMID 29872864 DOI: 10.1001/jamaoncol.2018.2297  1
2018 Teo MY, Bambury RM, Zabor EC, Jordan E, Al-Ahmadie H, Boyd ME, Bouvier N, Mullane SA, Cha EK, Roper N, Ostrovnaya I, Hyman DM, Bochner BH, Arcila ME, Solit DB, et al. Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma." Urologic Oncology. PMID 29859727 DOI: 10.1016/j.urolonc.2018.05.011  1
2018 Tao JJ, Schram AM, Harding JJ, Drilon A, Hyman DM. Learning All That We Can From MyPathway. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018784728. PMID 29856696 DOI: 10.1200/JCO.2018.78.4728  1
2018 Lowery MA, Ptashkin RN, Jordan EJ, Berger MF, Zehir A, Capanu M, Kemeny NE, O'Reilly EM, El Dika I, Jarnagin WR, Harding JJ, D'Angelica MI, Cercek A, Hechtman JF, Solit DB, ... ... Hyman DM, et al. Comprehensive molecular profiling of intra- and extrahepatic cholangiocarcinomas: potential targets for intervention. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29848569 DOI: 10.1158/1078-0432.Ccr-18-0078  1
2018 Yokota T, Bendell J, LoRusso P, Tsushima T, Desai V, Kenmotsu H, Watanabe J, Ono A, Murugesan B, Silva J, Naito T, Greenberg J, Kumar P, Wang Y, Jikoh T, ... ... Hyman DM, et al. Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials. British Journal of Cancer. PMID 29795308 DOI: 10.1038/s41416-018-0102-1  1
2018 LaVigne K, Hyman DM, Zhou QC, Iasonos A, Tew WP, Aghajanian C, Makker V, Hensley ML, Konner J, Grisham RN, Cangemi N, Soldan K, Spriggs DR, Sabbatini PJ, OʼCearbhaill RE. A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 29757876 DOI: 10.1097/IGC.0000000000001280  1
2018 van Beek EJAH, Hernandez JM, Goldman DA, Davis JL, McLaughlin K, Ripley RT, Kim TS, Tang LH, Hechtman JF, Zheng J, Capanu M, Schultz N, Hyman DM, Ladanyi M, Berger MF, et al. Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. Annals of Surgical Oncology. PMID 29725898 DOI: 10.1245/S10434-018-6502-X  1
2018 Catino AB, Hubbard RA, Chirinos JA, Townsend R, Keefe S, Haas NB, Puzanov I, Fang JC, Agarwal N, Hyman D, Smith AM, Gordon M, Plappert T, Englefield V, Narayan V, et al. Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma. Circulation. Heart Failure. 11: e004408. PMID 29664405 DOI: 10.1161/Circheartfailure.117.004408  1
2018 Bendell JC, Varghese AM, Hyman DM, Bauer TM, Pant S, Callies S, Lin J, Martinez R, Wickremsinhe ER, Fink A, Wacheck V, Moore KN. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29636360 DOI: 10.1158/1078-0432.CCR-17-3421  0.01
2018 Xu A, Hyman D, Lu LB. Cefazolin-Related Acute Interstitial Nephritis with Associated Nephrotic-Range Proteinuria: A Case Report. Drug Safety - Case Reports. 5: 16. PMID 29633042 DOI: 10.1007/s40800-018-0080-5  0.01
2018 Hyman DM, Rizvi NA, Natale RB, Armstrong DK, Birrer MJ, Recht L, Dotan E, Makker V, Kaley TJ, Kuruvilla D, Gribbin M, McDevitt J, Lai DW, Dar MM. Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined With Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29559563 DOI: 10.1158/1078-0432.Ccr-17-1775  1
2018 Chiang S, Cotzia P, Hyman DM, Drilon A, Tap WD, Zhang L, Hechtman JF, Frosina D, Jungbluth AA, Murali R, Park KJ, Soslow RA, Oliva E, Iafrate AJ, Benayed R, et al. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. The American Journal of Surgical Pathology. PMID 29553955 DOI: 10.1097/PAS.0000000000001055  1
2018 Lowery MA, Wong W, Jordan EJ, Lee JW, Kemel Y, Vijai J, Mandelker D, Zehir A, Capanu M, Salo-Mullen E, Arnold AG, Yu KH, Varghese AM, Kelsen DP, Brenner R, ... ... Hyman DM, et al. Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. Journal of the National Cancer Institute. PMID 29506128 DOI: 10.1093/Jnci/Djy024  1
2018 Bhatia A, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Lacouture ME, Hajdenberg J, Ganzel C, Diamond EL. Single-agent dabrafenib for BRAFV600E-mutated histiocytosis. Haematologica. PMID 29472347 DOI: 10.3324/haematol.2017.185298  1
2018 Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, ... ... Hyman DM, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. The New England Journal of Medicine. 378: 731-739. PMID 29466156 DOI: 10.1056/Nejmoa1714448  1
2018 Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 554: 189-194. PMID 29420467 DOI: 10.1038/Nature25475  1
2018 Ji Y, Jin JY, Hyman DM, Kim G, Suri A. Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology. Clinical and Translational Science. PMID 29392871 DOI: 10.1111/cts.12540  0.01
2018 Yaeger R, Chatila WK, Lipsyc MD, Hechtman JF, Cercek A, Sanchez-Vega F, Jayakumaran G, Middha S, Zehir A, Donoghue MTA, You D, Viale A, Kemeny N, Segal NH, Stadler ZK, ... ... Hyman DM, et al. Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell. 33: 125-136.e3. PMID 29316426 DOI: 10.1016/J.Ccell.2017.12.004  1
2017 Cunanan KM, Iasonos A, Shen R, Hyman DM, Riely GJ, Gönen M, Begg CB. Specifying the True- and False-Positive Rates in Basket Trials. Jco Precision Oncology. 1. PMID 32913969 DOI: 10.1200/PO.17.00181  1
2017 Shukla N, Roberts SS, Baki MO, Mushtaq Q, Goss PE, Park BH, Gundem G, Tian K, Geiger H, Redfield K, Behr G, Benayed R, Zehir A, Hechtman JF, Darnell RB, ... ... Hyman DM, et al. Successful Targeted Therapy of Refractory PediatricFusion-Positive Secretory Breast Carcinoma. Jco Precision Oncology. 2017. PMID 29623306 DOI: 10.1200/PO.17.00034  1
2017 Vaughan EM, Moreno JP, Hyman D, Chen TA, Foreyt JP. Efficacy of oral versus insulin therapy for newly diagnosed diabetes in low-income settings. Archives of General Internal Medicine. 1: 17-22. PMID 29517061  1
2017 Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, ... ... Hyman DM, et al. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer Discovery. PMID 29247021 DOI: 10.1158/2159-8290.Cd-17-1119  1
2017 Chang MT, Shrestha Bhattarai T, Schram AM, Bielski CM, Donoghue MTA, Jonsson P, Chakravarty D, Phillips S, Kandoth C, Penson A, Gorelick A, Shamu T, Patel S, Harris C, Gao J, ... ... Hyman DM, et al. Accelerating discovery of functional mutant alleles in cancer. Cancer Discovery. PMID 29247016 DOI: 10.1158/2159-8290.Cd-17-0321  1
2017 Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, Greenbaum B, Carroll J, Garon E, Hyman DM, Zehir A, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science (New York, N.Y.). PMID 29217585 DOI: 10.1126/Science.Aao4572  1
2017 Vaughan EM, Johnston CA, Hyman DJ, Hernandez DC, Hemmige V, Foreyt JP. Dual Therapy Appears Superior to Monotherapy for Low-Income Individuals With Newly Diagnosed Type 2 Diabetes. Journal of Primary Care & Community Health. 2150131917745760. PMID 29216790 DOI: 10.1177/2150131917745760  1
2017 Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, Lacouture M, Elez E, Martínez-Valle F, Durham B, Arcila ME, ... ... Hyman DM, et al. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. Jama Oncology. PMID 29188284 DOI: 10.1001/Jamaoncol.2017.5029  1
2017 Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila WK, Hechtman JF, Ku GY, Riches JC, Tuvy Y, Kundra R, Bouvier N, Vakiani E, Gao J, Heins ZJ, Gross BE, Kelsen DP, ... ... Hyman DM, et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discovery. PMID 29122777 DOI: 10.1158/2159-8290.Cd-17-0787  1
2017 Tao JJ, Schram AM, Hyman DM. Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology. Annual Review of Medicine. PMID 29120700 DOI: 10.1146/annurev-med-062016-050343  1
2017 Varghese AM, Arora A, Capanu M, Camacho N, Won HH, Zehir A, Gao J, Chakravarty D, Schultz N, Klimstra DS, Ladanyi M, Hyman DM, Solit DB, Berger MF, Saltz LB. Clinical and molecular characterization of patients with cancers of unknown primary in the modern era. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29045506 DOI: 10.1093/Annonc/Mdx545  1
2017 Yaeger R, Yao Z, Hyman DM, Hechtman JF, Vakiani E, Zhao H, Su W, Wang L, Joelson A, Cercek A, Baselga J, de Stanchina E, Saltz L, Berger MF, Solit DB, et al. Mechanisms of acquired resistance to BRAF V600E inhibition in colon cancers converge on RAF dimerization and are sensitive to its inhibition. Cancer Research. PMID 28951457 DOI: 10.1158/0008-5472.CAN-17-0768  1
2017 Schram AM, Reales D, Galle J, Cambria R, Durany R, Feldman D, Sherman E, Rosenberg J, D'Andrea G, Baxi S, Janjigian Y, Tap W, Dickler M, Baselga J, Taylor BS, ... ... Hyman DM, et al. Oncologist use and perception of large panel next-generation tumor sequencing. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: 2298-2304. PMID 28911072 DOI: 10.1093/Annonc/Mdx294  1
2017 Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, ... ... Hyman DM, et al. OncoKB: A Precision Oncology Knowledge Base. Jco Precision Oncology. 2017. PMID 28890946  1
2017 Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, Pradhan N, Arnold A, Walsh MF, Li Y, Balakrishnan AR, Syed A, Prasad M, Nafa K, Carlo MI, ... ... Hyman DM, et al. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. Jama. 318: 825-835. PMID 28873162 DOI: 10.1001/Jama.2017.11137  1
2017 Ulaner GA, Hyman DM, Lyashchenko SK, Lewis JS, Carrasquillo JA. 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. Clinical Nuclear Medicine. PMID 28872549 DOI: 10.1097/Rlu.0000000000001820  1
2017 Britt CJ, Hyman D, Hartig GK. Use of sialendoscopy as an aid to identify a large retained foreign body. Ear, Nose, & Throat Journal. 96: E18-E19. PMID 28846794  0.01
2017 Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, Danila D, Rathkopf D, Morris M, Slovin S, McLaughlin B, Curtis K, Hyman DM, Durack JC, Solomon SB, et al. Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. Jco Precision Oncology. 2017. PMID 28825054  1
2017 Coombs CC, Zehir A, Devlin SM, Kishtagari A, Syed A, Jonsson P, Hyman DM, Solit DB, Robson ME, Baselga J, Arcila ME, Ladanyi M, Tallman MS, Levine RL, Berger MF. Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell. PMID 28803919 DOI: 10.1016/J.Stem.2017.07.010  1
2017 Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, ... ... Hyman DM, et al. Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine. 23: 1004. PMID 28777785 DOI: 10.1038/nm0817-1004c  1
2017 Weigelt B, Comino-Méndez I, de Bruijn I, Tian L, Meisel JL, Garcia-Murillas I, Fribbens C, Cutts R, Martelotto LG, Ng CKY, Lim RS, Selenica P, Piscuoglio S, Aghajanian C, Norton L, ... ... Hyman DM, et al. Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28765325 DOI: 10.1158/1078-0432.CCR-17-0544  1
2017 Lowery MA, Jordan EJ, Basturk O, Ptashkin RN, Schultz N, Klimstra DS, Zehir A, Abou-Alfa GK, Allen PJ, Harding JJ, Hechtman JF, Jarnagin WR, Varghese AM, Yu KH, Schattner M, ... Hyman DM, et al. Real Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28754816 DOI: 10.1158/1078-0432.Ccr-17-0899  1
2017 Hechtman JF, Benayed R, Hyman DM, Drilon A, Zehir A, Frosina D, Arcila ME, Dogan S, Klimstra DS, Ladanyi M, Jungbluth AA. Pan-Trk Immunohistochemistry is an Efficient and Reliable Screen for the Detection of NTRK Fusions. The American Journal of Surgical Pathology. PMID 28719467 DOI: 10.1097/PAS.0000000000000911  1
2017 Drilon A, Nagasubramanian R, Blake JF, Ku N, Tuch BB, Ebata K, Smith S, Lauriault V, Kolakowski GR, Brandhuber BJ, Larsen PD, Bouhana KS, Winski SL, Hamor R, Wu WI, ... ... Hyman DM, et al. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. Cancer Discovery. PMID 28578312 DOI: 10.1158/2159-8290.Cd-17-0507  1
2017 Schram AM, Hyman DM. Quantifying the Benefits of Genome-Driven Oncology. Cancer Discovery. 7: 552-554. PMID 28576841 DOI: 10.1158/2159-8290.CD-17-0380  1
2017 Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, et al. AKT Inhibition in Solid Tumors With AKT1 Mutations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017730143. PMID 28489509 DOI: 10.1200/Jco.2017.73.0143  1
2017 Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, ... ... Hyman DM, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine. PMID 28481359 DOI: 10.1038/Nm.4333  1
2017 Hyman DJ. Hypertension: Does Polypharmacy Lead to Nonadherence or Nonadherence to Polypharmacy? Hypertension (Dallas, Tex. : 1979). PMID 28461603 DOI: 10.1161/HYPERTENSIONAHA.117.09334  0.01
2017 Hyman DJ, Pavlik V. Controlling Hypertension: We Have the Tools-We Just Need to Use Them. Journal of General Internal Medicine. PMID 28455646 DOI: 10.1007/s11606-017-4060-8  1
2017 Jordan EJ, Kim HR, Arcila ME, Barron DA, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, ... ... Hyman DM, et al. Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer Discovery. PMID 28336552 DOI: 10.1158/2159-8290.CD-16-1337  1
2017 Soumerai JD, Zelenetz AD, Moskowitz C, Palomba ML, Hamlin PA, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz S, Portlock C, Konner J, Gounder MM, Hyman DM, et al. The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28314788 DOI: 10.1158/1078-0432.CCR-16-3068  1
2017 Smyth LM, Monson KR, Jhaveri K, Drilon A, Li BT, Abida W, Iyer G, Gerecitano JF, Gounder M, Harding JJ, Voss MH, Makker V, Ho AL, Razavi P, Iasonos A, ... ... Hyman DM, et al. A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Investigational New Drugs. PMID 28281183 DOI: 10.1007/S10637-017-0445-0  1
2017 Hanker AB, Red Brewer M, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, et al. An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. Cancer Discovery. PMID 28274957 DOI: 10.1158/2159-8290.Cd-16-1431  1
2017 Schram AM, Aghajanian CA, Hyman DM. Niraparib in Recurrent Ovarian Cancer. The New England Journal of Medicine. 376: 801. PMID 28229583  1
2017 Schram AM, Berger MF, Hyman DM. Precision oncology: Charting a path forward to broader deployment of genomic profiling. Plos Medicine. 14: e1002242. PMID 28222135 DOI: 10.1371/journal.pmed.1002242  1
2017 Narayan V, Keefe SM, Haas N, Wang L, Puzanov I, Putt ME, Catino A, Fang J, Agarwal N, Hyman D, Smith AM, Finkelman BS, Narayan HK, Ewer S, ElAmm C, et al. Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28196874 DOI: 10.1158/1078-0432.Ccr-16-2869  1
2017 Hyman DM, Taylor BS, Baselga J. Implementing Genome-Driven Oncology. Cell. 168: 584-599. PMID 28187282 DOI: 10.1016/j.cell.2016.12.015  1
2017 Teo MY, Bambury R, Zabor EC, Jordan EJ, Al-Ahmadie HA, Boyd M, Bouvier N, Mullane S, Cha EK, Roper N, Ostrovnaya I, Hyman DM, Bochner BH, Arcila ME, Solit DB, et al. DNA Damage Response and Repair Gene Alterations Are Associated With Improved Survival In Patients With Platinum-Treated Advanced Urothelial Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28137924 DOI: 10.1158/1078-0432.Ccr-16-2520  1
2017 Narayan HK, Finkelman BS, French B, Plappert T, Hyman D, Smith AM, Margulies KB, Ky B. Detailed Echocardiographic Phenotyping in Breast Cancer Patients: Associations with Ejection Fraction Decline, Recovery, and Heart Failure Symptoms over 3 Years of Followup. Circulation. PMID 28104715 DOI: 10.1161/Circulationaha.116.023463  1
2017 Hyman DM, Sill MW, Lankes HA, Piekarz R, Shahin MS, Ridgway MR, Backes F, Tenney ME, Mathews CA, Hoffman JS, Aghajanian C, Hensley ML. A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. Gynecologic Oncology. 144: 96-100. PMID 28094040 DOI: 10.1016/J.Ygyno.2016.10.036  1
2017 D'souza A, Shishedo S, Spicer DV, Welter L, Jiang Y, Hyman DM, Solit DB, Ma CX, Bose R, Cutler RE, Eli L, Hicks JB, Kuhn P, Lu JM. Circulating tumor cells and genomic profiling of patients with ERBB2 mutant, HER2 non-amplified metastatic breast cancer treated with neratinib. Journal of Clinical Oncology. 35: e12554-e12554. DOI: 10.1200/Jco.2017.35.15_Suppl.E12554  1
2017 Hanker A, Brewer MR, Sheehan J, Koch J, Lanman R, Hyman D, Cutler R, Lalani A, Cross D, Lovly C, Meiler J, Arteaga C. Abstract P3-03-03: An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-03-03  1
2017 Schram A, Won HH, Andre F, Arnedos M, Bernstam FM, Bedard PL, Shaw KR, Horlings H, Micheel C, Park BH, Mann G, Lalani AS, Smyth L, Solit DB, Schrag D, ... ... Hyman DM, et al. Abstract LB-103: Landscape of somatic ERBB2 Mutations: Findings from AACR GENIE and comparison to ongoing ERBB2 mutant basket study Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-103  1
2017 Sullivan RJ, Janku F, Li BT, Wong D, Sosman J, Keedy V, Buchbinder E, Tolcher A, Varghese A, Hyman DM, Flaherty KT, Ribas A, Carvajal R, Wang-Gillam A, Kluger H, et al. Abstract CT003: Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients withBRAFandNRASmutant melanoma Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct003  1
2017 Hyman DM, Piha-Paul SA, Rodon J, Saura C, Shapiro GI, Quinn DI, Moreno V, Mayer IA, Arteaga C, Boni V, Calvo E, Loi S, Lockhart AC, Smyth LM, Erinjeri J, et al. Abstract CT001: Neratinib inHER2orHER3mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct001  1
2017 Penson A, Camacho N, Varghese AM, Abeshouse A, Razavi P, Syed A, Zehir A, Schultz N, Solit DB, Hyman D, Taylor BS, Berger MF. Abstract 971: Genome directed diagnosis informs clinical cancer care Cancer Research. 77: 971-971. DOI: 10.1158/1538-7445.Am2017-971  1
2017 Lipsyc M, Chatila W, Hechtman JF, Sanchez-Vega F, Middha S, Cercek A, Stadler Z, Kundra R, Syed A, Hyman DM, Zehir A, Shahrokni A, Varghese A, Reidy D, Segal NH, et al. Abstract 4380: Integrative genomics analysis of metastatic colorectal cancer Cancer Research. 77: 4380-4380. DOI: 10.1158/1538-7445.Am2017-4380  1
2017 Schram AM, Reales D, Galle J, Cambria R, Durany R, Feldman D, Sherman E, Rosenberg J, D'Andrea G, Baxi S, Janjigian Y, Tap W, Dickler M, Baselga J, Taylor B, ... ... Hyman DM, et al. Abstract 375: Oncologist use and perception of large panel next generation tumor sequencing Cancer Research. 77: 375-375. DOI: 10.1158/1538-7445.Am2017-375  1
2016 Paik M, Black B, Hyman DA. Damage caps and defensive medicine, revisited. Journal of Health Economics. 51: 84-97. PMID 28129637 DOI: 10.1016/j.jhealeco.2016.11.001  1
2016 Ross DS, Zehir A, Cheng DT, Benayed R, Nafa K, Hechtman JF, Janjigian YY, Weigelt B, Razavi P, Hyman DM, Baselga J, Berger MF, Ladanyi M, Arcila ME. Next-Generation Assessment of ERBB2 (Human Epidermal Growth Factor Receptor 2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay. The Journal of Molecular Diagnostics : Jmd. PMID 28027945 DOI: 10.1016/J.Jmoldx.2016.09.010  1
2016 Schram AM, Iasonos A, Hyman DM. Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 4312-4314. PMID 27998226 DOI: 10.1200/JCO.2016.69.7169  1
2016 Schram AM, Voss MH, Hyman DM. Genome-Driven Paradigm for the Development of Selective Fibroblast Growth Factor Receptor Inhibitors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016705061. PMID 27918716 DOI: 10.1200/JCO.2016.70.5061  1
2016 Gostin LO, Hyman DA, Jacobson PD. The Affordable Care Act: Moving Forward in the Coming Years. Jama. PMID 27893878 DOI: 10.1001/Jama.2016.18908  0.01
2016 Cunanan KM, Gonen M, Shen R, Hyman DM, Riely GJ, Begg CB, Iasonos A. Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016699751. PMID 27893325 DOI: 10.1200/JCO.2016.69.9751  1
2016 Momtaz P, Pentsova E, Abdel-Wahab O, Diamond E, Hyman D, Merghoub T, You D, Gasmi B, Viale A, Chapman PB. Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget. PMID 27863426 DOI: 10.18632/oncotarget.13397  1
2016 Yang C, Arnold AG, Trottier M, Sonoda Y, Abu-Rustum NR, Zivanovic O, Robson ME, Stadler ZK, Walsh MF, Hyman DM, Offit K, Zhang L. Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family. Breast Cancer Research and Treatment. PMID 27757719 DOI: 10.1007/s10549-016-4021-7  1
2016 Whelton PK, Einhorn PT, Muntner P, Appel LJ, Cushman WC, Diez Roux AV, Ferdinand KC, Rahman M, Taylor HA, Ard J, Arnett DK, Carter BL, Davis BR, Freedman BI, Cooper LA, ... ... Hyman DJ, et al. Research Needs to Improve Hypertension Treatment and Control in African Americans. Hypertension (Dallas, Tex. : 1979). PMID 27620388 DOI: 10.1161/Hypertensionaha.116.07905  1
2016 Manus MK, Roy S, Stag R, Hyman D. Non-compaction cardiomyopathy in an asymptomatic athlete. Bmj Case Reports. 2016. PMID 27535732 DOI: 10.1136/bcr-2016-216339  1
2016 Diamond EL, Hatzoglou V, Patel S, Abdel-Wahab O, Rampal R, Hyman DM, Holodny AI, Raj A. Diffuse reduction of cerebral grey matter volumes in Erdheim-Chester disease. Orphanet Journal of Rare Diseases. 11: 109. PMID 27484739 DOI: 10.1186/S13023-016-0490-3  1
2016 Morris LG, Chandramohan R, West L, Zehir A, Chakravarty D, Pfister DG, Wong RJ, Lee NY, Sherman EJ, Baxi SS, Ganly I, Singh B, Shah JP, Shaha AR, Boyle JO, ... ... Hyman DM, et al. The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform. Jama Oncology. PMID 27442865 DOI: 10.1001/Jamaoncol.2016.1790  1
2016 Hyman DA, Saha S, Nayar HS, Doyle JF, Agarwal SK, Chaiet SR. Patterns of Facial Fractures and Protective Device Use in Motor Vehicle Collisions From 2007 to 2012. Jama Facial Plastic Surgery. PMID 27441732 DOI: 10.1001/jamafacial.2016.0733  0.01
2016 Ulaner GA, Hyman D, Ross D, Corben A, Chandarlapaty S, Goldfarb S, McArthur H, Erinjeri J, Solomon S, Kolb H, Lyashchenko S, Lewis J, Carrasquillo J. Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using the 89Zr-DFO-trastuzumab PET/CT. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27151988 DOI: 10.2967/Jnumed.115.172031  1
2016 Narayan HK, French B, Khan AM, Plappert T, Hyman D, Bajulaiye A, Domchek S, DeMichele A, Clark A, Matro J, Bradbury A, Fox K, Carver JR, Ky B. Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction. Jacc. Cardiovascular Imaging. PMID 27085442 DOI: 10.1016/J.Jcmg.2015.11.024  1
2016 Hyman DM, Eaton A, Ivy SP, Spriggs DR, Iasonos A. Measuring Toxicity in Phase I Clinical Trials-Letter. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 22: 1828. PMID 27037257 DOI: 10.1158/1078-0432.CCR-15-3043  1
2016 Eubank MH, Hyman DM, Kanakamedala AD, Gardos SM, Wills JM, Stetson PD. Automated eligibility screening and monitoring for genotype-driven precision oncology trials. Journal of the American Medical Informatics Association : Jamia. PMID 27016727 DOI: 10.1093/jamia/ocw020  1
2016 Drilon A, Eaton AA, Schindler K, Gounder MM, Spriggs DR, Harris P, Ivy SP, Iasonos A, Lacouture ME, Hyman DM. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program. Cancer. PMID 26916138 DOI: 10.1002/cncr.29918  1
2016 Drilon A, Li G, Dogan S, Gounder M, Shen R, Arcila M, Wang L, Hyman DM, Hechtman J, Wei G, Cam NR, Christiansen J, Luo D, Maneval EC, Bauer T, et al. What hides behind the MASC: Clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 26884591 DOI: 10.1093/annonc/mdw042  1
2016 Hyman DM, Solit DB, Iasonos A. Reply to M.P. Decatris et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 887. PMID 26755514 DOI: 10.1200/JCO.2015.65.2487  1
2016 Jordan E, Lowery MA, Ptashkin R, Zehir A, Berger MF, Maynard H, Glassman DC, Covington CM, Schultz N, Abou-Alfa GK, Harding JJ, Klimstra DS, Hechtman JF, Hyman DM, Allen PJ, et al. Genomic profiling of pancreas ductal adenocarcinoma (PDA), actionability, and correlation with clinical phenotype. Journal of Clinical Oncology. 34: 4127-4127. DOI: 10.1200/Jco.2016.34.15_Suppl.4127  1
2016 Zehir A, Coombs CC, Devlin S, Kishtagari A, Hyman DM, Solit DB, Robson ME, Baselga J, Arcila ME, Tallman MS, Levine RL, Berger MF. Prevalence of clonal hematopoiesis in patients with advanced cancer. Journal of Clinical Oncology. 34: 1511-1511. DOI: 10.1200/Jco.2016.34.15_Suppl.1511  1
2016 Coombs CC, Zehir A, Devlin S, Kishtagari A, Hyman DM, Solit D, Robson M, Baselga J, Arcila M, Tallman MS, Levine RL, Berger M. Mutational Analysis of Clonal Hematopoiesis in Solid Tumor Patients Illustrates the Critical Role of Systemic Anti-Cancer Therapies in the Evolution of Somatic Leukemia Disease Alleles Blood. 128: 37-37. DOI: 10.1182/Blood.V128.22.37.37  1
2016 Razavi P, Chang MT, Middha S, Ross DS, Zehir A, Proverbs-Singh TA, Kandoth C, Chandarlapaty S, Dickler MN, Reis-Filho JS, Patil S, Seshan V, Smyth L, Iyengar NM, Jhaveri K, ... ... Hyman D, et al. Abstract 4509: Clinical genomic profiling of 1000 metastatic breast cancer patients: actionable targets, novel alterations, and clinical correlations Cancer Research. 76: 4509-4509. DOI: 10.1158/1538-7445.Am2016-4509  1
2016 Coombs C, Zehir A, Devlin S, Middha S, Cheng D, Kishtagari A, Hyman D, Solit D, Robson M, Baselga J, Arcila M, Tallman M, Levine R, Berger M. Abstract 2640: Clonal hematopoiesis identified by matched-normal blood sequencing of solid tumor patients without hematologic malignancy is common and is associated with decreased overall survival Epidemiology. 76: 2640-2640. DOI: 10.1158/1538-7445.Am2016-2640  1
2016 Kovacic WE, Hyman DA. Consume or invest: What do/should agency leaders maximize? Washington Law Review. 91: 295-324.  1
2015 Davenport SM, Suidan RS, Huang J, Hyman DM, Chi DS. Primary debulking surgery for metastatic cervical adenocarcinoma: A case report. Gynecologic Oncology Reports. 14: 23-5. PMID 26793767 DOI: 10.1016/j.gore.2015.09.004  1
2015 Hechtman JF, Zehir A, Yaeger RD, Wang L, Middha S, Zheng T, Hyman D, Solit D, Arcila ME, Borsu L, Shia J, Vakiani E, Saltz L, Ladanyi M. Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma that are Preferentially Associated with Wild Type RAS/RAF. Molecular Cancer Research : McR. PMID 26660078 DOI: 10.1158/1541-7786.Mcr-15-0392-T  1
2015 Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z, Choi J, Kim E, Cohen-Aubart F, Lee SC, Gao Y, Micol JB, Campbell P, Walsh MP, ... ... Hyman DM, et al. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery. PMID 26566875 DOI: 10.1182/Blood.V126.23.481.481  1
2015 Schrader KA, Cheng DT, Joseph V, Prasad M, Walsh M, Zehir A, Ni A, Thomas T, Benayed R, Ashraf A, Lincoln A, Arcila M, Stadler Z, Solit D, Hyman D, et al. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. Jama Oncology. 1-8. PMID 26556299 DOI: 10.1001/jamaoncol.2015.5208  1
2015 Mueller JJ, Holzapfel M, Han CH, Santos K, Gunderson C, Moore K, Erickson B, Leath CA, Diaz E, Walsh C, Wethington SL, Dejbakhsh SZ, Barakat RR, Gardner GJ, Hyman DM, et al. Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 26509849 DOI: 10.1097/IGC.0000000000000559  1
2015 Eaton A, Iasonos A, Gounder MM, Pamer EG, Drilon A, Vulih D, Smith GL, Ivy SP, Spriggs DR, Hyman DM. Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26324741 DOI: 10.1158/1078-0432.CCR-15-0339  1
2015 Grisham RN, Sylvester BE, Won H, McDermott G, DeLair D, Ramirez R, Yao Z, Shen R, Dao F, Bogomolniy F, Makker V, Sala E, Soumerai TE, Hyman DM, Socci ND, et al. Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26324360 DOI: 10.1200/JCO.2015.62.4726  1
2015 Hyman DM, Solit DB, Arcila ME, Cheng DT, Sabbatini P, Baselga J, Berger MF, Ladanyi M. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discovery Today. PMID 26320725 DOI: 10.1016/j.drudis.2015.08.005  1
2015 Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. The New England Journal of Medicine. 373: 726-36. PMID 26287849 DOI: 10.1056/NEJMoa1502309  1
2015 Marcus BC, Hyman D. Evidence-Based Medicine in Laser Medicine for Facial Plastic Surgery. Facial Plastic Surgery Clinics of North America. 23: 297-302. PMID 26208768 DOI: 10.1016/j.fsc.2015.04.003  1
2015 Hyman DM, Solit DB. Tumor Genetic Screening Programs: A Call to Action. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 2725-6. PMID 26195721 DOI: 10.1200/JCO.2015.61.9296  1
2015 Hyman DA, Studdert DM. Emergency Medical Treatment and Labor Act: what every physician should know about the federal antidumping law. Chest. 147: 1691-6. PMID 26033130 DOI: 10.1378/chest.14-2046  1
2015 Rao TD, Tian H, Ma X, Yan X, Thapi S, Schultz N, Rosales N, Monette S, Wang A, Hyman DM, Levine DA, Solit D, Spriggs DR. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion. Plos One. 10: e0126633. PMID 25965947 DOI: 10.1371/journal.pone.0126633  1
2015 Pavlik VN, Chan W, Hyman DJ, Feldman P, Ogedegbe G, Schwartz JE, McDonald M, Einhorn P, Tobin JN. Evaluating Health Systems Level Hypertension Control Interventions for African-Americans: Lessons from a Pooled Analysis of Three Cluster Randomized Trials. Current Hypertension Reviews. PMID 25808682 DOI: 10.2174/1573402111666150325234503  1
2015 Hyman DM, Eaton AA, Gounder MM, Pamer EG, Pettiford J, Carvajal RD, Ivy SP, Iasonos A, Spriggs DR. Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials. Oncotarget. PMID 25682870  1
2015 Hyman DM, Snyder AE, Carvajal RD, Gerecitano JF, Voss MH, Ho AL, Konner J, Winkelmann JL, Stasi MA, Monson KR, Iasonos A, Spriggs DR, Bialer P, Lacouture ME, Teitcher JB, et al. Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 75: 747-55. PMID 25672916 DOI: 10.1007/s00280-015-2693-z  1
2015 Meisel JL, Hyman DM, Jotwani A, Zhou Q, Abu-Rustum NR, Iasonos A, Pike MC, Aghajanian C. The role of systemic chemotherapy in the management of granulosa cell tumors. Gynecologic Oncology. 136: 505-11. PMID 25546114 DOI: 10.1016/J.Ygyno.2014.12.026  1
2015 Hyman DM, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, Holley VR, Cabrilo G, Lu TT, Arcila ME, Chung YR, Rampal R, Lacouture ME, Rosen N, Meric-Bernstam F, et al. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discovery. 5: 64-71. PMID 25324352 DOI: 10.1182/Blood.V124.21.1833.1833  1
2015 Hyman DJ, Pavlik V. Medication adherence and resistant hypertension. Journal of Human Hypertension. 29: 213-8. PMID 25209307 DOI: 10.1038/jhh.2014.73  1
2015 Hyman DM, Sill M, Cho JK, Lankes HA, Piekarz R, Hensley ML. A phase II study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-0231D). Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E16512  1
2015 Bambury RM, Jordan E, Zabor EC, Bouvier N, Al-Ahmadie H, Boyd ME, Mullane SA, Cha EK, Ostrovnaya I, Hyman DM, Bochner BH, Arcila ME, Solit DB, Bajorin DF, Bellmunt J, et al. Association of somatic mutations in DNA damage repair (DDR) genes with efficacy of platinum-based chemotherapy in advanced urothelial carcinoma. Journal of Clinical Oncology. 33: 4532-4532. DOI: 10.1200/Jco.2015.33.15_Suppl.4532  1
2015 Coombs CC, Zehir A, Devlin S, Middha S, Cheng D, Kishtagari A, Hyman DM, Solit D, Robson M, Baselga J, Arcila M, Ladanyi M, Tallman MS, Levine RL, Berger M. Next-Generation Sequencing of Matched Normal Blood Identifies Clonal Hematopoiesis in a Significant Subset of Solid Tumor Patients without Hematologic Malignancies Blood. 126: 2447-2447. DOI: 10.1182/Blood.V126.23.2447.2447  1
2015 Bagrodia A, Iyer G, Cha E, Boyd M, Zehir A, Cheng D, Hyman D, Al-Ahmadie H, Bambury R, Arcila M, Ladanyi M, Viale A, Michael B, Bochner B, Rosenberg J, et al. Mp64-02 Comparison Of Genetic Alterations From The Cancer Genome Atlas Bladder Cancer Analysis And A Prospective Set Of High-Grade Urothelial Carcinoma Tumors Using A Clinical Laboratory Improvement Amendments-Certified Next Generation Sequencing Assay The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2313  1
2015 Hyman DA, Kovacic WE. Why who does what matters: Governmental design and agency performance George Washington Law Review. 82: 1446-1516.  1
2014 Meisel JL, Hyman DM, Garg K, Zhou Q, Dao F, Bisogna M, Gao J, Schultz ND, Grisham RN, Phillips M, Iasonos A, Kauff ND, Levine DA, Soslow RA, Spriggs DR. The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 2372-8. PMID 25281711 DOI: 10.1093/annonc/mdu461  1
2014 Emile JF, Diamond EL, Hélias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Hyman DM, Kim E, Rampal R, Patel M, Ganzel C, Aumann S, Faucher G, Le Gall C, Leroy K, Colombat M, et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood. 124: 3016-9. PMID 25150293 DOI: 10.1182/blood-2014-04-570937  1
2014 Hyman DM, Eaton AA, Gounder MM, Ivy SP, Iasonos A, Spriggs DR. Reply to M. Voskoboynik et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3199-200. PMID 25071117 DOI: 10.1200/JCO.2014.56.5762  1
2014 Rakotz MK, Ewigman BG, Sarav M, Ross RE, Robicsek A, Konchak CW, Gavagan TF, Baker DW, Hyman DJ, Anderson KP, Masi CM. A technology-based quality innovation to identify undiagnosed hypertension among active primary care patients. Annals of Family Medicine. 12: 352-8. PMID 25024244 DOI: 10.1370/Afm.1665  1
2014 Hyman DA, Sage WM. We have strict statutes and most biting laws--reply. Jama Internal Medicine. 174: 1203. PMID 25003894 DOI: 10.1001/jamainternmed.2014.765  1
2014 Grisham RN, Iyer G, Sala E, Zhou Q, Iasonos A, DeLair D, Hyman DM, Aghajanian C. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 24: 1010-4. PMID 24978709 DOI: 10.1097/IGC.0000000000000190  1
2014 Grisham RN, Hyman DM, Iyer G. Targeted therapies for treatment of recurrent ovarian cancer. Clinical Advances in Hematology & Oncology : H&O. 12: 158-62. PMID 24927263  1
2014 Beylergil V, Carrasquillo JA, Hyman DM, Diamond EL. Visualization of orbital involvement of Erdheim-Chester disease on PET/CT. Clinical Nuclear Medicine. 39: 660-1. PMID 24873784 DOI: 10.1097/RLU.0000000000000452  1
2014 Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, Ferrarini M, Abdel-Wahab O, Heaney ML, Scheel PJ, Feeley NK, Ferrero E, McClain KL, Vaglio A, Colby T, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 124: 483-92. PMID 24850756 DOI: 10.1182/blood-2014-03-561381  1
2014 Hyman DM, Grisham RN, Hensley ML. Management of advanced uterine leiomyosarcoma. Current Opinion in Oncology. 26: 422-7. PMID 24840518 DOI: 10.1097/CCO.0000000000000094  1
2014 Sage WM, Hyman DA. Malpractice reform: the authors reply. Health Affairs (Project Hope). 33: 519. PMID 24590955 DOI: 10.1377/hlthaff.2014.0077  1
2014 Bohn OL, Hsu K, Hyman DM, Pignataro DS, Giralt S, Teruya-Feldstein J. BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation. Clinical Lymphoma, Myeloma & Leukemia. 14: e65-8. PMID 24445188 DOI: 10.1016/j.clml.2013.12.003  1
2014 Hyman DM, Eaton AA, Gounder MM, Smith GL, Pamer EG, Hensley ML, Spriggs DR, Ivy P, Iasonos A. Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 519-26. PMID 24419130 DOI: 10.1200/JCO.2013.49.8808  1
2014 Sage WM, Hyman DA. Let's make a deal: trading malpractice reform for health reform. Health Affairs (Project Hope). 33: 53-8. PMID 24395935 DOI: 10.1377/hlthaff.2013.0006  1
2014 McGuckin M, Govednik J, Hyman D, Black B. Public reporting of health care-associated infection rates: are consumers aware and engaged? American Journal of Medical Quality : the Official Journal of the American College of Medical Quality. 29: 83-5. PMID 23880774 DOI: 10.1177/1062860613495441  1
2014 Damberg CL, Hyman D, France J. Do public reports of provider performance make their data and methods available and accessible? Medical Care Research and Review : McRr. 71: 81S-96S. PMID 23838150 DOI: 10.1177/1077558713493670  1
2014 Hyman DM, Rizvi NA, Natale RB, Armstrong DK, Birrer MJ, Recht LD, Dotan E, Gribbin MJ, McDevitt JT, Tavakkoli F, McCaffrey J, Sikorski R, Lai DW. A phase 1 study of MEDI3617, a selective angiopoietin-2 inhibitor, alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizumab in patients with advanced solid tumors. Journal of Clinical Oncology. 32: 3012-3012. DOI: 10.1200/Jco.2014.32.15_Suppl.3012  1
2014 Tawbi HA, Chu E, Lin Y, Hyman DM, Goel S, Rudek MA, Dowlati A, LoRusso P, Mulkerin D, Chew HK, Kiesel B, Pollice L, Appleman LJ, Puhalla S, Stoller RG, et al. Early phase I study of the PARP inhibitor veliparib (ABT-888) alone or in combination with carboplatin/paclitaxel (CP) in patients with varying degrees of hepatic or renal dysfunction: A study of the NCI-Organ Dysfunction Working Group (ODG). Journal of Clinical Oncology. 32: 2572-2572. DOI: 10.1200/Jco.2014.32.15_Suppl.2572  1
2014 Hyman DA. Why did law professors misunderestimate the lawsuits against ppaca University of Illinois Law Review. 2014: 805-838.  1
2014 Hyman DA. Constitutional prognostication: Does anybody knows anything? University of Illinois Law Review. 2014: 1279-1292.  1
2014 Hyman DA, Franklyn DJ. Trademarks as search-engine keywords: Who, what, when? Texas Law Review. 92: 2117-2150.  1
2013 Hyman DA, Cohen PR. Stasis dermatitis as a complication of recurrent levofloxacin-associated bilateral leg edema. Dermatology Online Journal. 19: 20399. PMID 24314775  1
2013 McGuckin M, Govednik J, Hyman D, Black B. Public reporting of healthcare-associated infections: epidemiologists' perspectives. Infection Control and Hospital Epidemiology. 34: 1201-3. PMID 24113605 DOI: 10.1086/673458  1
2013 Hyman DA, Sage WM. Medical malpractice in the outpatient setting: through a glass, darkly. Jama Internal Medicine. 173: 2069-70. PMID 24081110 DOI: 10.1001/jamainternmed.2013.9193  1
2013 Diamond EL, Abdel-Wahab O, Pentsova E, Borsu L, Chiu A, Teruya-Feldstein J, Hyman DM, Rosenblum M. Detection of an NRAS mutation in Erdheim-Chester disease. Blood. 122: 1089-91. PMID 23929840 DOI: 10.1182/blood-2013-02-482984  1
2013 Grigoryan L, Pavlik VN, Hyman DJ. Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulatory blood pressure and high medication adherence. Journal of the American Society of Hypertension : Jash. 7: 471-6. PMID 23890931 DOI: 10.1016/j.jash.2013.06.004  1
2013 Kemper C, Blackburn C, Doyle JA, Hyman D. Engaging patients and families in system-level improvement: a safety imperative. Nursing Administration Quarterly. 37: 203-15. PMID 23744466 DOI: 10.1097/Naq.0B013E318295F61E  1
2013 Hyman DA, Silver C. Response. Chest. 143: 1835-6. PMID 23732603 DOI: 10.1378/chest.13-0473  1
2013 Amini A, Birnbaum DW, Black B, Hyman DA. Public reporting of hospital infection rates: ranking the states on credibility and user friendliness. Studies in Health Technology and Informatics. 183: 87-92. PMID 23388261 DOI: 10.3233/978-1-61499-203-5-87  1
2013 Grigoryan L, Pavlik VN, Hyman DJ. Patterns of nonadherence to antihypertensive therapy in primary care. Journal of Clinical Hypertension (Greenwich, Conn.). 15: 107-11. PMID 23339728 DOI: 10.1111/jch.12030  1
2013 Hyman DA, Silver C. Five myths of medical malpractice. Chest. 143: 222-7. PMID 23276845 DOI: 10.1378/chest.12-1916  1
2013 Hyman DM, Bakios L, Gualtiere G, Carr C, Grisham RN, Makker V, Sonoda Y, Aghajanian C, Jewell EL. Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome. Gynecologic Oncology. 129: 58-62. PMID 23274560 DOI: 10.1016/j.ygyno.2012.12.029  1
2013 Hyman DA. Something went wrong on the way to the courthouse. Journal of Health Politics, Policy and Law. 38: 243-53. PMID 23262776 DOI: 10.1215/03616878-1966234  1
2013 Grisham RN, Iyer G, Garg K, DeLair D, Hyman DM, Zhou Q, Iasonos A, Berger MF, Dao F, Spriggs DR, Levine DA, Aghajanian C, Solit DB. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. 119: 548-54. PMID 22930283 DOI: 10.1002/cncr.27782  1
2013 Mansyur CL, Pavlik VN, Hyman DJ, Taylor WC, Goodrick GK. Self-efficacy and barriers to multiple behavior change in low-income African Americans with hypertension. Journal of Behavioral Medicine. 36: 75-85. PMID 22322910 DOI: 10.1007/S10865-012-9403-7  1
2013 Paik M, Black B, Hyman D. The Receding Tide of Medical Malpractice Litigation: Part 2-Effect of Damage Caps Journal of Empirical Legal Studies. 10: 639-669. DOI: 10.1111/jels.12022  1
2013 Hyman D. Testimony of David Hyman, General Counsel, Netflix. Inc, hearing on "the future of video", Online Video Distributors: An Exploration of Legal and Regulatory Issues. 57-59.  1
2013 Hyman DA, Kovacic WE. Institutional design, agency life cycle, and the goals of competition law Fordham Law Review. 81: 2163-2174.  1
2012 Iasonos A, Gounder M, Spriggs DR, Gerecitano JF, Hyman DM, Zohar S, O'Quigley J. The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5179-87. PMID 22825582 DOI: 10.1158/1078-0432.Ccr-12-0726  1
2012 Hyman D, Laire M, Redmond D, Kaplan DW. The use of patient pictures and verification screens to reduce computerized provider order entry errors Pediatrics. 130. PMID 22665415 DOI: 10.1542/peds.2011-2984  1
2012 Grisham RN, Adaniel C, Hyman DM, Ma W, Iasonos A, Aghajanian C, Konner J. Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 22: 807-11. PMID 22635030 DOI: 10.1097/IGC.0b013e31824a33a2  1
2012 Hyman DM, Long KC, Tanner EJ, Grisham RN, Arnold AG, Bhatia J, Phillips MF, Spriggs DR, Soslow RA, Kauff ND, Levine DA. Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. Gynecologic Oncology. 126: 224-8. PMID 22579790 DOI: 10.1016/j.ygyno.2012.05.001  1
2012 Hyman D, Morales-Vidal S, Schneck MJ. Antithrombotic therapy for stroke prevention in patients with heart failure. Current Treatment Options in Cardiovascular Medicine. 14: 215-26. PMID 22451325 DOI: 10.1007/s11936-012-0177-6  1
2012 Grigoryan L, Pavlik VN, Hyman DJ. Predictors of antihypertensive medication adherence in two urban health-care systems. American Journal of Hypertension. 25: 735-8. PMID 22441507 DOI: 10.1038/ajh.2012.30  1
2012 Hyman DM, Spriggs DR. Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer. Jama. 307: 408-10. PMID 22274690 DOI: 10.1001/jama.2012.24  1
2012 Cheung LK, Agi R, Hyman DJ. Warfarin resistance associated with parenteral nutrition. The American Journal of the Medical Sciences. 343: 255-8. PMID 22143126 DOI: 10.1097/MAJ.0b013e3182382553  1
2012 Hyman DM, Zhou Q, Iasonos A, Grisham RN, Arnold AG, Phillips MF, Bhatia J, Levine DA, Aghajanian C, Offit K, Barakat RR, Spriggs DR, Kauff ND. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer. 118: 3703-9. PMID 22139894 DOI: 10.1002/cncr.26655  1
2012 Konner J, Grisham RN, Park J, O'Connor OA, Cropp G, Johnson R, Hannah AL, Hensley ML, Sabbatini P, Mironov S, Miranov S, Danishefsky S, Hyman D, Spriggs DR, Dupont J, et al. Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma. Investigational New Drugs. 30: 2294-302. PMID 22072399 DOI: 10.1007/s10637-011-9765-7  1
2012 Hyman DJ, Pavlik VN, Greisinger AJ, Chan W, Bayona J, Mansyur C, Simms V, Pool J. Effect of a physician uncertainty reduction intervention on blood pressure in uncontrolled hypertensives--a cluster randomized trial. Journal of General Internal Medicine. 27: 413-9. PMID 22033742 DOI: 10.1007/S11606-011-1888-1  1
2012 Hyman DA, Silver C. Justice Has (Almost) Nothing to Do With It: Medical Malpractice and Tort Reform Medicine and Social Justice: Essays On the Distribution of Health Care. DOI: 10.1093/acprof:osobl/9780199744206.003.0043  1
2012 Hyman DJ, Vallbona C, Pavlik VN. Hypertension in Hispanics Hypertension: a Companion to Braunwald's Heart Disease: Second Edition. 365-368. DOI: 10.1016/B978-1-4377-2766-1.00041-7  1
2011 Hyman DM, Zhou Q, Arnold AG, Grisham RN, Bhatia J, Aghajanian C, Iasonos A, Spriggs DR, Kauff ND. Topoisomerase I inhibition in BRCA+ and BRCA- ovarian cancer (OC): A single-institution experience. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e15557. PMID 28023713 DOI: 10.1200/jco.2011.29.15_suppl.e15557  1
2011 Grisham RN, Adaniel CH, Hyman DM, Ma W, Iasonos A, Aghajanian C, Konner JA. Gemcitabine for advanced endometrial carcinoma (EMC): A review of the MSKCC experience. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 5098. PMID 28023639 DOI: 10.1200/jco.2011.29.15_suppl.5098  1
2011 Hyman DM, Soff GA, Kampel LJ. Disseminated intravascular coagulation with excessive fibrinolysis in prostate cancer: a case series and review of the literature. Oncology. 81: 119-25. PMID 21986538 DOI: 10.1159/000331705  0.01
2011 Hyman DM, Zhou Q, Arnold AG, Grisham RN, Iasonos A, Kauff ND, Spriggs D. Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Gynecologic Oncology. 123: 196-9. PMID 21855118 DOI: 10.1016/j.ygyno.2011.07.019  1
2011 Hyman DA, Black B, Silver C. Settlement at Policy Limits and the Duty to Settle: Evidence from Texas Journal of Empirical Legal Studies. 8: 48-84. DOI: 10.1111/j.1740-1461.2010.01207.x  1
2011 Hyman DA. Convicts and convictions: Some lessons from transportation for health reform University of Pennsylvania Law Review. 159: 1999-2042.  1
2010 Bedi G, Hyman D, de Wit H. Is ecstasy an "empathogen"? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biological Psychiatry. 68: 1134-40. PMID 20947066 DOI: 10.1016/J.Biopsych.2010.08.003  1
2010 Hyman DA. Follow the money: money matters in health care, just like in everything else. American Journal of Law & Medicine. 36: 370-88. PMID 20726401  1
2010 Scarlata CJ, Hyman DA. Development and validation of a fast high pressure liquid chromatography method for the analysis of lignocellulosic biomass hydrolysis and fermentation products Journal of Chromatography A. 1217: 2082-2087. PMID 20202640 DOI: 10.1016/j.chroma.2010.01.061  1
2010 Khan R, Hyman D. Hematochezia in the young patient: a review of health-seeking behavior, physician attitudes, and controversies in management. Digestive Diseases and Sciences. 55: 233-9. PMID 19238544 DOI: 10.1007/s10620-009-0750-3  1
2010 Hyman DA. Health Care Fragmentation The Fragmentation of U.S. Health Care: Causes and Solutions. DOI: 10.1093/acprof:oso/9780195390131.003.002  1
2010 Park TH, Hyman D, Leonard P, Wu W. Systematic and Quantative Electro-acoustic Music Analysis (SQEMA) International Computer Music Conference, Icmc 2010. 199-206.  1
2009 Pavlik VN, Greisinger AJ, Pool J, Haidet P, Hyman DJ. Does reducing physician uncertainty improve hypertension control?: rationale and methods. Circulation. Cardiovascular Quality and Outcomes. 2: 257-63. PMID 20031846 DOI: 10.1161/CIRCOUTCOMES.109.849984  1
2009 Hyman DJ, Taffet GE. Blood pressure control in the elderly: can you have too much of a good thing? Current Hypertension Reports. 11: 337-42. PMID 19737450 DOI: 10.1007/s11906-009-0057-y  1
2009 Hyman DA. Employment-based health insurance and universal coverage: four things people know that aren't so. Yale Journal of Health Policy, Law, and Ethics. 9: 435-52. PMID 19725389  1
2009 Neuspiel DR, Hyman D, Lane M. Quality Improvement and Patient Safety in the Pediatric Ambulatory Setting: Current Knowledge and Implications for Residency Training Pediatric Clinics of North America. 56: 935-951. PMID 19660636 DOI: 10.1016/j.pcl.2009.05.011  1
2009 Hyman DA. Health insurance Labor and Employment Law and Economics. 172-182.  1
2009 Abramson E, Hyman D, Osorio N, Kaushal R. Implementing a patient safety and quality program across two merged pediatric institutions Joint Commission Journal On Quality and Patient Safety. 35: 43-48.  1
2008 Volk RJ, Jibaja-Weiss ML, Hawley ST, Kneuper S, Spann SJ, Miles BJ, Hyman DJ. Entertainment education for prostate cancer screening: a randomized trial among primary care patients with low health literacy. Patient Education and Counseling. 73: 482-9. PMID 18760888 DOI: 10.1016/j.pec.2008.07.033  1
2008 Ghodsian B, Bogdanoff P, Hyman D. Wideband DC-contact MEMS series switch Micro and Nano Letters. 3: 63-69. DOI: 10.1049/mnl:20080009  1
2008 Hyman DA. On my mind Forbes. 182: 34.  1
2008 Hyman DJ. RF MEMS hybrid package testing International Conference and Exhibition On Device Packaging 2009. 3: 1375-1404.  1
2007 Lin G, Spann S, Hyman D, Pavlik V. Climate amenity and BMI. Obesity (Silver Spring, Md.). 15: 2120-7. PMID 17712131 DOI: 10.1038/oby.2007.252  1
2007 Hyman DJ, Pavlik VN, Taylor WC, Goodrick GK, Moye L. Simultaneous vs sequential counseling for multiple behavior change. Archives of Internal Medicine. 167: 1152-8. PMID 17563023 DOI: 10.1001/Archinte.167.11.1152  1
2007 Parikh S, Hyman D. Hepatocellular cancer: a guide for the internist. The American Journal of Medicine. 120: 194-202. PMID 17349437 DOI: 10.1016/j.amjmed.2006.11.020  1
2007 Hyman DA. Institutional review boards: Is this the least worst we can do? Northwestern University Law Review. 101: 749-773.  1
2006 Gavagan TF, Smart K, Palacio H, Dyer C, Greenberg S, Sirbaugh P, Fishkind A, Hamilton D, Shah U, Masi G, Ivey RT, Jones J, Chiou-Tan FY, Bloodworth D, Hyman D, et al. Hurricane Katrina: medical response at the Houston Astrodome/Reliant Center Complex. Southern Medical Journal. 99: 933-9. PMID 17004527 DOI: 10.1097/00007611-200609000-00012  1
2006 Hyman DA, Sage WM. Subsidizing health care providers through the tax code: status or conduct? Health Affairs (Project Hope). 25: W312-5. PMID 16787934 DOI: 10.1377/hlthaff.25.w312  1
2006 Hyman DA, Jacobson P. Is a dose of competition just what the doctor ordered? Journal of Health Politics, Policy and Law. 31: 423-35. PMID 16785291 DOI: 10.1215/03616878-2005-001  1
2006 Hyman DA. The social context of competition policy: Endnote Journal of Health Politics, Policy and Law. 31: 705-706. DOI: 10.1215/03616878-2005-015  1
2006 Hyman DA. Rescue without law: An empirical perspective on the duty to rescue Texas Law Review. 84: 653-737.  1
2006 Hyman DA. Getting the haves to come out behind: Fixing the distributive injustices of American health caare Law and Contemporary Problems. 69: 265-282.  1
2006 Hyman DA, Silver C. Medical malpractice litigation and tort reform: It's the incentives, stupid Vanderbilt Law Review. 59: 1085-1136.  1
2006 Hyman DJ, Kuroda R. Flip-chip assembly of RF MEMS for microwave hybrid circuitry Proceedings of the Asme/Pacific Rim Technical Conference and Exhibition On Integration and Packaging of Mems, Nems, and Electronic Systems: Advances in Electronic Packaging 2005. 2053-2056.  1
2005 Bitondo Dyer C, Toronjo C, Cunningham M, Festa NA, Pavlik VN, Hyman DJ, Poythress EL, Searle NS. The key elements of elder neglect:a survey of adult protective service workers. Journal of Elder Abuse & Neglect. 17: 1-10. PMID 17050489  1
2005 Hyman DA, Silver C. The poor state of health care quality in the U.S.: is malpractice liability part of the problem or part of the solution? Cornell Law Review. 90: 893-993. PMID 15954245  1
2005 Lin SX, Hyman D, Larson E. Provision of health counseling in office-based practices and hospital outpatient clinics Preventive Medicine. 40: 542-546. PMID 15749136 DOI: 10.1016/J.Ypmed.2004.06.015  1
2005 Pavlik VN, Hyman DJ, Doody R. Cardiovascular risk factors and cognitive function in adults 30-59 years of age (NHANES III). Neuroepidemiology. 24: 42-50. PMID 15459509 DOI: 10.1159/000081049  1
2004 Pavlik VN, Hyman DJ, Wendt JA, Orengo C. Association of a culturally defined syndrome (nervios) with chest pain and DSM-IV affective disorders in Hispanic patients referred for cardiac stress testing. Ethnicity & Disease. 14: 505-14. PMID 15724769  1
2004 Hyman DA, Kovacic WE. Monopoly, monopsony, and market definition: an antitrust perspective on market concentration among health insurers. Health Affairs (Project Hope). 23: 25-8. PMID 15537581 DOI: 10.1377/hlthaff.23.6.25  1
2004 Hyman DA. Five reasons why health care quality research hasn't affected competition law and policy. International Journal of Health Care Finance and Economics. 4: 159-66. PMID 15211104 DOI: 10.1023/B:IHFE.0000032421.54279.c6  1
2004 Hyman DA, Silver C. Believing six improbable things: Medical malpractice and "legal fear", Harvard Journal of Law and Public Policy. 28: 107-118.  1
2003 Hyman DA. An outsider perspective on intellectual property discourse. Advances in Genetics. 50: 275-86; discussion 5. PMID 14714696 DOI: 10.1016/S0065-2660(03)50014-1  1
2003 Hyman D. Reorganizing health systems to promote best practice medical care, patient self-management, and family-centered care for childhood asthma Ethnicity and Disease. 13. PMID 14552463  1
2003 Wayne DB, Greenberg SB, Pavlik VN, Helmer DA, Hyman DJ. Ambulatory internal medicine education: use of an urgent care center. Southern Medical Journal. 96: 876-9. PMID 14513983 DOI: 10.1097/01.SMJ.0000054938.43211.7A  1
2003 Assadi M, Baseman S, Hyman D. Tc SPECT scan in a patient with occipital lobe infarction and complex visual hallucinations The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses. 35: 175-177. PMID 12830666  1
2003 Pavlik VN, Hyman DJ. How well are we managing and monitoring high blood pressure? Current Opinion in Nephrology and Hypertension. 12: 299-304. PMID 12698069 DOI: 10.1097/01.mnh.0000069864.94246.d0  1
2003 Sage WM, Hyman DA, Greenberg W. Why competition law matters to health care quality. Health Affairs (Project Hope). 22: 31-44. PMID 12674406 DOI: 10.1377/hlthaff.22.2.31  1
2003 Hyman DA. Does medicare care about quality? Perspectives in Biology and Medicine. 46: 55-68. PMID 12582270  1
2003 Pavlik VN, de Moraes SA, Szklo M, Knopman DS, Mosley TH, Hyman DJ. Relation between cognitive function and mortality in middle-aged adults: the atherosclerosis risk in communities study. American Journal of Epidemiology. 157: 327-34. PMID 12578803 DOI: 10.1093/Aje/Kwf209  1
2003 Hyman DJ, Pavlik VN. Uncontrolled hypertension as a risk for coronary artery disease: patient characteristics and the role of physician intervention. Current Atherosclerosis Reports. 5: 131-8. PMID 12573199  1
2003 Hyman DA. Does technology spell trouble with a capital "T"?: Human dignity and public policy Harvard Journal of Law and Public Policy. 27: 3-18.  1
2003 Gurgevich EA, Hyman D, Alter TR. Creation of UniSCOPE: A model for rewarding all forms of scholarship Journal of Asynchronous Learning Network. 7.  1
2002 Hyman DJ, Pavlik VN. Poor hypertension control: let's stop blaming the patients. Cleveland Clinic Journal of Medicine. 69: 793-9. PMID 12371802  1
2002 Hyman DJ, Henry A, Taylor A. Severe rhabdomyolysis related to cerivastatin without gemfibrozil. Annals of Internal Medicine. 137: 74. PMID 12093260  1
2002 Harrell R, Toronjo CH, McLaughlin J, Pavlik VN, Hyman DJ, Dyer CB. How geriatricians identify elder abuse and neglect. The American Journal of the Medical Sciences. 323: 34-8. PMID 11814140  1
2002 Hyman DA. HIPAA and health care fraud: An empirical perspective Cato Journal. 22: 151-178.  1
2002 Patel MP, Reshotko E, Hyman D. Microfabricated shear-stress sensors, Part 3: Reducing calibration uncertainty Aiaa Journal. 40: 1582-1588.  1
2001 Hyman DA, Hall M. Two cheers for employment-based health insurance Yale Journal of Health Policy, Law, and Ethics. 2: 23-57. PMID 12664936  1
2001 Hyman DA. Health care fraud and abuse: Market change, social norms, and the trust "reposed in the workmen", Journal of Legal Studies. 30: 531. PMID 12647746  1
2001 Wayne DB, Trajtenberg CP, Hyman DJ. Tooth and periodontal disease: a review for the primary-care physician. Southern Medical Journal. 94: 925-32. PMID 11592756  1
2001 Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. The New England Journal of Medicine. 345: 479-86. PMID 11519501 DOI: 10.1056/NEJMoa010273  1
2001 Hyman DA, Silver C. Just what the patient ordered: The case for result-based compensation arrangements Journal of Law, Medicine and Ethics. 29: 170-173. PMID 11508193  1
2001 Vasandani G, Hyman DJ, Pavlik V. Other factors in self-reported hypertension treatment practices among primary care physicians [1] (multiple letters) Archives of Internal Medicine. 161: 1458. PMID 11386898  1
2001 Hyman DA. What lessons should we learn from drive-through deliveries? Pediatrics. 107: 406-408. PMID 11158476 DOI: 10.1542/peds.107.2.406  1
2001 Hyman D, Bridger J, Shingler J, Van Loon M. Paradigms, policies, and people: Exploring the linkages between normative beliefs, public policies and utility consumer payment problems Policy Studies Review. 18: 89-121.  1
2000 Hyman DA. Regulating managed care: What's wrong with a patient bill of rights Southern California Law Review. 73: 221. PMID 12731503  1
2000 Hyman DJ, Pavlik VN, Vallbona C. Physician Role in Lack of Awareness and Control of Hypertension. Journal of Clinical Hypertension (Greenwich, Conn.). 2: 324-330. PMID 11416669  1
2000 Pavlik VN, Hyman DJ, Toronjo C. Comparison of Automated and Mercury Column Blood Pressure Measurements in Health Care Settings. Journal of Clinical Hypertension (Greenwich, Conn.). 2: 81-86. PMID 11416630  1
2000 Hyman DA. Do good stories make for good policy? Journal of Health Politics, Policy and Law. 25: 1149-1155. PMID 11142055  1
2000 Hyman DA. Medicine in the new millennium: A self-help guide for the perplexed American Journal of Law and Medicine. 26: 143-154. PMID 10953768  1
2000 Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Archives of Internal Medicine. 160: 2281-6. PMID 10927724  1
2000 Pettignano R, Holloway SE, Hyman D, LaBuz M. Is the Leak Test Reproducible? Southern Medical Journal. 93: 683-685. PMID 10923956  1
1999 Hyman DA. Managed care at the millennium: Scenes from a Maul Journal of Health Politics, Policy and Law. 24: 1061-1070. PMID 10615617  1
1999 Bang CA, Pan T, Hyman DJ. Micromachined heat sinks Sae Technical Papers. DOI: 10.4271/1999-01-1408  1
1999 Hyman D, Pan T, Reshotko E, Mehregany M. Microfabricated shear stress sensors, part 2: Testing and calibration Aiaa Journal. 37: 73-78. DOI: 10.2514/2.666  1
1999 Pan T, Hyman D, Mehregany M, Reshotko E, Garverick S. Microfabricated shear stress sensors, part 1: Design and fabrication Aiaa Journal. 37: 66-72. DOI: 10.2514/2.665  1
1999 Hyman D, Mehregany M. Contact physics of gold microcontacts for MEMS switches Ieee Transactions On Components and Packaging Technologies. 22: 357-364. DOI: 10.1109/6144.796533  1
1999 Hyman D, Shingler J. The hierarchy of consumer participation and patterns of economic, social, and political participation Journal of Consumer Affairs. 33: 380-407.  1
1998 Hyman DA, Silver C. IVF shared-risk programs The Journal of Law, Medicine &Amp; Ethics : a Journal of the American Society of Law, Medicine &Amp; Ethics. 26: 79-80. PMID 11067595  1
1998 Hyman DA. Patient dumping and EMTALA: past imperfect/future shock Health Matrix (Cleveland, Ohio : 1991). 8: 29-56. PMID 10179281  1
1998 Frazier S, Hyman D, Altschuler S. The changing health care environment: Implications for residency training Pediatrics. 101: 795-804. PMID 9544185  1
1998 Hyman DA. A second opinion on second opinions Virginia Law Review. 84: 1439.  1
1997 Manski RJ, Peddicord D, Hyman D. Medicaid, Managed Care, and America's Health Safety Net Journal of Law, Medicine and Ethics. 25: 30-33. PMID 11066472  1
1996 Hyman DW. The regulation of health claims in food advertising: Have the FTC and the FDA finally reached a common ground? Food and Drug Law Journal. 51: 191-205. PMID 11794351  1
1996 Kiefe CI, Hyman DJ. Do public clinic systems provide health care access for the urban poor? A cross-sectional survey. Journal of Community Health. 21: 61-70. PMID 8903584 DOI: 10.1007/Bf01682764  1
1996 Pavlik VN, Hyman DJ, Vallbona C. Hypertension control in multi-ethnic primary care clinics. Journal of Human Hypertension. 10: S19-23. PMID 8872819  1
1994 Vallbona C, Hyman DJ. Improving health care for the poor. Jama. 272: 352-3; author reply . PMID 8028158 DOI: 10.1001/jama.1994.03520050029015  1
1992 Hyman DJ, Paradis G, Flora JA. A comparison of participants and nonparticipants in a worksite cholesterol screening American Journal of Health Promotion. 7: 137-141. PMID 10148718  1
1992 Hyman DJ, Barrett DC, Fortmann SP. Effect of minor illness on serum cholesterol level. American Journal of Preventive Medicine. 8: 100-3. PMID 1599716  1
1992 Hyman D, Gutman LT. Prophylactic use of trimethoprim-sulfamethoxazole in children with recurrent otitis media Pediatric Infectious Disease Journal. 11: 685. PMID 1523088  1
1992 Hyman DA. Professional profiteering? The ethics of physician entrepreneurship Perspectives in Biology and Medicine. 35: 318-329. PMID 1501995  1
1992 Hyman DM. Discrete analysis in commutative rings Journal of Mathematical Analysis and Applications. 171: 537-554. DOI: 10.1016/0022-247X(92)90364-J  1
1992 Hyman DM. A theory of discrete analysis Journal of Mathematical Analysis and Applications. 169: 374-390. DOI: 10.1016/0022-247X(92)90085-R  1
1991 Hyman DA. Peer review: current law and policy problems Healthspan. 8: 3-10. PMID 10114029  1
1991 Varela M, Shapira E, Hyman DB. Ullrich-Turner syndrome in mother and daughter: Prenatal diagnosis of a 46,X,del(X)(p21) offspring from a 45,X mother with low-level mosaicism for the del(X)(p21) in one ovary American Journal of Medical Genetics. 39: 411-412. PMID 1877618  1
1991 Hyman D, Wadsworth M, Alexander DP. Values, policy-making, and implementation: The Roots of Bias in Utility Regulatory and Energy Mediation Policy Administration &Amp; Society. 23: 310-332. DOI: 10.1177/009539979102300303  1
1990 Hyman DA. Aesthetics and ethics: The implications of cosmetic surgery Perspectives in Biology and Medicine. 33: 190-202. PMID 2304820  1
1990 Hyman DA. Conflicts of Interest, Continued Jama: the Journal of the American Medical Association. 263: 1199-1200. PMID 2304232 DOI: 10.1001/jama.1990.03440090029015  1
1990 Hyman DA. The conundrum of charitability: Reassessing tax exemption for hospitals American Journal of Law and Medicine. 16: 327-380. PMID 2278243  1
1990 Hyman DA. How law killed ethics Perspectives in Biology and Medicine. 34: 134-151. PMID 2274401  1
1990 Berenson RA, Hyman DA. When opportunity knocks The Hastings Center Report. 20: 33-35; discussion 33. PMID 2135168  1
1990 Hyman DN. Using marginal benefit curves to illustrate income and substitution effects Journal of Economic Education. 21: 383-387. DOI: 10.1080/00220485.1990.10844683  1
1988 Hyman DA, McCarthy TJ. Property tax exemptions: headed for extinction? Health Progress (Saint Louis, Mo.). 69: 32-6. PMID 10290831  1
1988 Malone C, Spellman S, Hyman D, Rothman-Denes LB. Cloning and generation of a genetic map of bacteriophage N4 DNA Virology. 162: 328-336. PMID 3341115 DOI: 10.1016/0042-6822(88)90472-2  1
1988 Tanaka K, Ikeda Y, Matsubara Y, Hyman D. Molecular basis of isovaleric acidemia and the study of the acyl-CoA dehydrogenase family Advances in Neurology. 48: 107-131. PMID 3275439  1
1988 Geme JWS, Hyman D. Hepatic injury during rotavirus infections The Journal of Pediatrics. 113: 952-953. PMID 2903230 DOI: 10.1016/S0022-3476(88)80044-1  1
1988 Hyman DA. It’s Over, Debbie Jama: the Journal of the American Medical Association. 259: 2097. DOI: 10.1001/jama.1988.03720140018021  1
1987 Hyman DW. Epidemiology of eye disease in the elderly Eye (Basingstoke). 1: 330-341. PMID 3653439 DOI: 10.1038/eye.1987.53  1
1987 Hyman D, Parkum K, Parkum V. Models of Health and Human Services in the Nonprofit Sector Nonprofit and Voluntary Sector Quarterly. 16: 4-5. DOI: 10.1177/089976408701600402  1
1987 Ram CVS, Hyman D. Hypertensive Crises Journal of Intensive Care Medicine. 2: 151-162. DOI: 10.1177/088506668700200305  1
1986 Haas A, Stiehm ER, Hyman D. The 'yeast connection' meets chronic mucocutaneous candidiasis New England Journal of Medicine. 314: 854-855. PMID 3951526  1
1986 Hyman DB, Tanaka K. Isovaleryl-CoA dehydrogenase activity in isovaleric acidemia fibroblasts using an improved tritium release assay Pediatric Research. 20: 59-61. PMID 3753755 DOI: 10.1203/00006450-198601000-00017  1
1986 Hyman D. Prosuming, Participation, Consumer Education and the Deregulation of Telecommunications Nonprofit and Voluntary Sector Quarterly. 15: 7-23. DOI: 10.1177/089976408601500303  1
1986 Sinha VT, Butensky MS, Hyman D. Comparison of cylinders and spheres in three-phase fluidization Industrial &Amp; Engineering Chemistry Process Design and Development. 25: 321-324.  1
1986 Schatzel SJ, Hyman DM, Sainato A. CASE STUDY OF METHANE OCCURRENCES AT THE CATHEDRAL BLUFFS SHALE OIL MINE, COLORADO Oil Shale Symposium Proceedings. 38-46.  1
1985 Hyman D, Kaplan NM. The difference between serum and plasma potassium New England Journal of Medicine. 313: 642. PMID 4022056  1
1985 Hyman D, Kaplan NM. Treatment of patients with mild hypertension Hypertension. 7: 165-170. PMID 3884501  1
1984 Hyman DB, Tanaka K. Specific glutaryl-CoA dehydrogenating activity is deficient in cultured fibroblasts from glutaric aciduria patients Journal of Clinical Investigation. 73: 778-784. PMID 6423663  1
1984 Hyman D. Deciding on medical care for endangered newborns: Substantive and procedural issues Einstein Quarterly Journal of Biology and Medicine. 2: 185-190.  1
1984 Sinha VT, Butensky M, Hyman D. THREE-PHASE FLUIDIZATION OF POLYDISPERSE BEADS Aiche Symposium Series. 80: 176-185.  1
1983 Hyman DB, Saunders AM, Tanaka K. A rapid spot test for urinary methylmalonic acid collected on ion-exchange filter paper. Clinica Chimica Acta; International Journal of Clinical Chemistry. 132: 219-27. PMID 6616877 DOI: 10.1016/0009-8981(83)90001-3  1
1983 Hyman D. A preventive approach to bureaucracy: The dialectical organization as a model for citizen's Advocacy and Ombudsmen Nonprofit and Voluntary Sector Quarterly. 12: 65-80. DOI: 10.1177/089976408301200408  1
1983 Hyman D. Advocacy in the New World: Introduction To the Special Issue Nonprofit and Voluntary Sector Quarterly. 12: 9-10. DOI: 10.1177/089976408301200404  1
1983 Allen TJ, Hyman DB, Pinckney DL. Transferring technology to the small manufacturing firm: A study of technology transfer in three countries Research Policy. 12: 199-211. DOI: 10.1016/0048-7333(83)90002-1  1
1983 Malone RE, Hyman D. Interactions Between the MAT locus and the rad52-1 mutation in yeast Current Genetics. 7: 439-447. DOI: 10.1007/Bf00377609  1
1982 Bullington B, Katkin D, Hyman D. RHETORIC AND REALITY IN THE REFORM OF JUVENILE JUSTICE POLICY Review of Policy Research. 2: 230-238. DOI: 10.1111/j.1541-1338.1982.tb00668.x  1
1980 Peavy DL, Koff WC, Hyman DS, Knight V. Inhibition of lymphocyte proliferative responses by ribavirin Infection and Immunity. 29: 583-589. PMID 7216427  1
1980 Brosio G, Hyman DN, Santagata W. Revenue sharing and local public spending: The Italian experience Public Choice. 35: 3-15. DOI: 10.1007/BF00154744  1
1980 Magargal LE, Augsburger JJ, Hyman D, Townsend R. Venous macroaneurysm following branch retinal vein obstruction Annals of Ophthalmology. 12: 685-688.  1
1979 Chase JD, Skrivan JF, Hyman D, Longfield JE. Plasma jet process for making elemental phosphorus Industrial and Engineering Chemistry Process Design and Development. 18: 261-266.  1
1977 Hyman D, Griffiths D, Ungar B. Pathways to community services: The effect of differential information sources on patterns of participation Nonprofit and Voluntary Sector Quarterly. 6: 59-68. DOI: 10.1177/089976407700600108  1
1973 HYMAN DS. Cements at Teotihuacan: A Criticism of Margain's Appraisal American Anthropologist. 75: 313-314. DOI: 10.1525/aa.1973.75.1.02a00290  1
1972 Pai VK, Hyman D. Heating of a Thin Yarn on an Internally Heated Rotating Roll: Part II: Yarn-Temperature History Textile Research Journal. 42: 639-645. DOI: 10.1177/004051757204201103  1
1972 Pai VK, Hyman D. Heating of a Thin Yarn on an Internally Heated Rotating Roll: Part I: Roll-Surface Temperature Textile Research Journal. 42: 633-639. DOI: 10.1177/004051757204201102  1
1972 Pai VK, Hyman D. Heating of a thin yarn on an internally heated rotating roll. I. Roll surface temperature 1
1972 Pai VK, Hyman D. Heating of a thin yarn on an internally heated rotating roll. II. Yarn-temperature history 1
1971 Butensky M, Hyman D. Rotary drum granulation. An experimental study of the factors affecting granule size Industrial and Engineering Chemistry Fundamentals. 10: 212-219.  1
1970 Widom A, Hyman DS. Evaporation of He3 atoms from liquid He3-He4 mixtures Physical Review A. 2: 818-820. DOI: 10.1103/Physreva.2.818  1
1969 Hyman DS, Scully MO, Widom A. Evaporation from superfluid helium Physical Review. 186: 231-238. DOI: 10.1103/Physrev.186.231  1
1969 Hyman DM. A note on closed maps and metrizability Proceedings of the American Mathematical Society. 21: 109-112. DOI: 10.1090/S0002-9939-1969-0238258-7  1
1969 Hyman DS. Note on Hartree models of the superfluid helium film Physics Letters A. 30: 466-467.  1
1967 Hyman DM. A generalization of the borsukwhitehead-hanner theorem Pacific Journal of Mathematics. 23: 263-271.  1
1963 HYMAN D. Plantar warts newer treatments New York State Journal of Medicine. 63: 1680-1681. PMID 13956013  1
1963 Montgomery RM, Hyman D. Mosaic Warts of the Hand Archives of Dermatology. 87: 391-392. DOI: 10.1001/archderm.1963.01590150107022  1
1962 Hyman D. Mixing and Agitation Advances in Chemical Engineering. 3: 119-202. DOI: 10.1016/S0065-2377(08)60059-9  1
1962 Hyman D, Corson WB. On-stream analog computer for residence-time experiments Iandec Process Design and Development. 1: 92-96.  1
1961 LEAHEY EB, HYMAN D, HAWKES LP. Ochronosis The New Zealand Medical Journal. 61: 951-954. PMID 13759912  1
1961 HYMAN D, BREZAK S. Granuloma annulare: a clinical note Journal of the American Podiatry Association. 51: 126-127. PMID 13717166  1
1960 HYMAN D. Andrew H. Montgomery Archives of Dermatology. 82: 429-430. PMID 14405726  1
Show low-probability matches.